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ABSTRACT
METHODS FOR COMPARATIVE EFFECTIVENESS RESEARCH WITH REAL WORLD DATA
Joanna Grace Harton
Rebecca A. Hubbard
Nandita Mitra
Electronic health records (EHR) contain a wealth of information that can potentially be used for
research. EHR is particularly valuable for accelerating comparative effectiveness research, which
seeks to estimate the relative benefit of alternative treatments in real-world settings. However there
are also many challenges and limitations to conducting research with EHR-derived data, including
measurement error, systematic differences between EHR and trial populations, and differential
quantity and quality of data available across patients. In this dissertation, we first investigate the
performance of several methods for mitigating bias due to measurement error applied to propensity
scores created from error-prone covariates and provide recommendations for which methods to
use in certain scenarios. Next, we develop a method to augment a randomized clinical trial with
EHR data in order to create a hybrid control arm. This new method, data-adaptive-weighting, has
promising properties when compared to more standard methods as well as another more recent
propensity score-based method. Finally, we investigate the scenario of informed presence bias in
longitudinal data, which arises when some subjects have more information in the EHR than others
based on their intensity of utilization. We extend current work and explore several scenarios in
which adjusting for biomarker values obtained at both pre-scheduled and patient-initiated visits in
order to determine when there is risk of bias. For each topic we applied alternative methods to realworld EHR-derived data to demonstrate practical implications of alternative approaches in realistic
settings.
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CHAPTER 1
I NTRODUCTION
Electronic Health Records (EHR) contain a vast amount of data and are therefore an important
resource for answering a variety of research questions without the need for primary data collection.
This also allows for research to be conducted that would be difficult to study otherwise due to
feasibility or ethical considerations. In particular, EHR contain information at the patient- and visitlevel, recording demographic characteristics, medications prescribed, diagnoses, lab values, and
more. However, EHR were not designed for research purposes, they were developed for clinical
care and billing purposes. Some of the information that may be of interest to a researcher may
lie in free-text notes or may not be recorded at all. Additionally, many countries without universal
healthcare have a fragmented system such that records across healthcare systems are not often
linked, leading to large amounts of missing information. Not only may information be missing, it is
also common for error to be present in EHR, whether through data-entry, laboratory machine error,
or other measures. While these issues may seem insurmountable, there is much research being
conducted with EHR and on the best way to use EHR in analyses.
In particular, we focus on three separate issues regarding the use of EHR data: error in confounders, the combination of EHR with clinical trial data, and informative presence bias. It is known
that if there is error in confounders, the validity of the results using such confounders in the analysis
are questionable (Carroll et al., 2006; Guo, Little, and McConnell, 2012; Rosner, Spiegelman, and
Willett, 1990). However, to the best of our knowledge past research has focused on correcting the
error in each individual confounder rather than creating a function of the error-prone confounders,
such as a propensity score, and correcting for error in the propensity score directly. It can be
appealing to consider combining EHR data with clinical trial data in order to augment the standardof-care arm with real world patients in order to complete a randomized clinical trial more quickly
(Schmidli et al., 2020; Ventz et al., 2019). Nearly all current work focuses on up- or down-weighting
the EHR data as a whole depending on similarity to the trial control subjects and neglects to take
into account the heterogeneity of the individual subjects (Chen, Ibrahim, and Shao, 2000; Duan
and Ye, 2008; Ibrahim and Chen, 2000; Neuenschwander, Branson, and Spiegelhalter, 2009). Finally, it also must be considered that individuals who have a greater burden of co-morbidity are
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likely to interact with the healthcare system more than subjects who are healthier (Goldstein et al.,
2016; Phelan, Bhavsar, and Goldstein, 2017; Weiskopf, Rusanov, and Weng, 2013). This differential interaction can be particularly problematic when using longitudinal data due to potentially large
differences in the amount of information collected on ‘healthy’ versus ‘sick’ individuals.
In Chapter 2 we review approaches to account for error in propensity scores and used simulation
studies to compare their performance. While methods exist to address measurement error in individual covariates, little prior research has investigated the implications of using propensity scores for
confounder control when the propensity scores are constructed from a combination of accurate and
error-prone covariates. These comparisons were conducted across a range of scenarios featuring
variation in outcome type, validation sample size, main sample size, strength of confounding, and
structure of the error in the mismeasured covariate. We then applied these approaches to a realworld EHR-based comparative effectiveness study of alternative treatments for metastatic bladder
cancer. This head-to-head comparison of measurement error correction methods in the context of
a propensity score-adjusted analysis demonstrated that multiple imputation for propensity scores
performs best when the outcome is continuous and regression calibration-based methods perform
best when the outcome is binary.
In Chapter 3 we develop a novel method for incorporating EHR data into the control arm of a randomized clinical trial, creating a hybrid control arm. We propose a new method for analyses of
trials with a hybrid control arm that efficiently controls bias and type I error. Under our proposed
approach, selected real-world patients are weighted by a function of the “on-trial score,” which reflects their similarity to trial patients. In contrast to previously developed hybrid control designs
that assign the same weight to all real-world patients, our approach upweights real-world patients
who more closely resemble randomized control patients while dissimilar patients are discounted.
Estimates of the treatment effect are obtained via Cox proportional hazards models. We compare
our approach to existing approaches via simulations and apply these methods to a study using
pseudo-electronic health record data. Our proposed method is able to control type I error, minimize
bias, and decrease variance when compared to using only trial data in nearly all scenarios examined. Therefore, our new approach can be used when conducting clinical trials by augmenting the
standard-of-care arm with weighted patients from the EHR to increase power without inducing bias.
In Chapter 4 we extend current work examining how using EHR data can result in biased effect
2

estimates, particularly when the way in which patients interact with the healthcare system can result
in informed presence bias where those who have poorer health have more data recorded than those
who are healthier. We extend existing work by examining various scenarios of a biomarker’s effect
on a health event when there is also a covariate that affects both the informative visit process and
the outcome. Using biomarker values gathered at both informative and non-informative visits when
estimating the effect of the biomarker on the event of interest is likely a reasonable option when
conducting analyses but we caution that bias may still remain and can be significant in certain
scenarios.
In Chapter 5 we end with a brief discussion of our work in the broader context of comparative
effectiveness research and discuss potential extensions of our work.
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CHAPTER 2
B IAS R EDUCTION M ETHODS

FOR

P ROPENSITY S CORES E STIMATED

FROM

E RROR -P RONE EHR-D ERIVED C OVARIATES
2.1. Introduction
Data from Electronic Health Records (EHR) have the potential to facilitate research on exposures
and outcomes that would be difficult to study using designed observational or experimental studies due to feasibility or ethical considerations. However, because EHR were developed for clinical
care and administrative purposes, the data elements needed for research are often incomplete or
error-prone. Many recent studies have highlighted data quality challenges arising in EHR-based
research (Hersh et al., 2013; Rusanov et al., 2014; Weiskopf and Weng, 2013). Statistical methods
to account for missing and error-prone data are needed in order for valid research results to be obtained from the available EHR. Without appropriate analytic approaches treatment effect estimates
obtained from error-prone EHR data may be biased, and standard errors are likely to be incorrect.
While EHR databases can provide extensive information for large study populations and many outcomes, causal conclusions can be difficult to draw and confounding can lead to biased treatment
effect estimates. Unlike randomized trials, the factors influencing whether a patient receives a treatment of interest are uncertain. Estimated propensity scores, which are the probability of receiving
treatment conditional on observed covariates, are often used for confounder control (Rosenbaum
and Rubin, 1983).
Error in confounder variables presents a particularly serious challenge to the validity of EHR-based
research. Prior statistical methods research has shown that the use of error-prone confounders results in biased treatment effect estimates due to residual confounding (Carroll et al., 2006; Guo, Little, and McConnell, 2012; Rosner, Spiegelman, and Willett, 1990). Thus, while propensity scores,
under identifying assumptions, offer the possibility of deriving causal conclusions from EHR, error
in the confounder variables used to construct the propensity score potentially undermines the effectiveness of this approach. Although a number of methods exist that account for measurement error
and misclassification in covariates (Carroll et al., 2006; Cole, Chu, and Greenland, 2006; Guo,
Little, and McConnell, 2012; Rosner, Spiegelman, and Willett, 1990; Webb-Vargas et al., 2017),
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few of these methods have been evaluated in the context of a propensity score estimated from
error-prone covariate information (Steiner, Cook, and Shadish, 2011).
A variety of methods to address measurement error are available, although they are infrequently
used in the context of analyses using EHR-derived propensity scores. Regression calibration accounts for measurement error by regressing the true covariate on its error-prone analog in a validation sample to generate predictions for the true covariate in the full sample. It has been used
as a benchmark for performance of measurement error correction approaches against which other
methods are compared due to its frequent use in some research settings (Rosner, Spiegelman,
and Willett, 1990). One would expect this method to perform well when the error-prone version of
the covariate differs from the true covariate in a systematic way, such as if the error-prone covariate
represents systematic inflation of the true covariate by a fixed factor (Carroll et al., 2006). When
the error-prone covariate is, on average, a good estimate for the true covariate but has random
error present the performance of regression calibration will depend on the amount of noise in the
error-prone covariate. Propensity score calibration, which is regression calibration applied to a propensity score instead of a covariate, has been proposed to account for error in propensity scores
arising due to omission of key covariates from the propensity score model (Sturmer et al., 2005).
A modification of regression calibration is Monte Carlo regression calibration. Instead of treating the
coefficients in the calibration model as fixed and known, they are drawn from a multivariate normal
distribution and the outcome model is fit multiple times, combining results across imputations (Cole,
Chu, and Greenland, 2006). This method has been compared to regular regression calibration, but
only in the context of error-prone covariates, not propensity scores (Cole, Chu, and Greenland,
2006; Freedman et al., 2008; Messer and Natarajan, 2008)
Efficient regression calibration is a modification of regression calibration that uses a weighted combination of the regression calibration estimator and the estimate of the treatment effect obtained
from the validation subset (Spiegelman, Carroll, and Kipnis, 2001). The efficient regression calibration estimator is expected to perform well in the same kind of scenarios in which standard regression
calibration performs well. However, the performance of efficient regression calibration has not yet
been evaluated in the context of propensity scores estimated using error-prone covariates.
Similar to efficient regression calibration, two-stage calibration uses a weighted combination of
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the treatment effect estimated from a validation subset in which true covariate data are available
and the estimate based on the error-prone covariate available in the full sample (Lin and Chen,
2014). This method is expected to perform well when the estimate of the treatment effect in the
validation subset is a good estimate of the treatment effect in the full sample, had the true value
been available for all subjects (Lin and Chen, 2014). While this method has been evaluated in
analyses using propensity scores constructed from error-prone covariates, it was only compared
head-to-head against regression calibration (Lin and Chen, 2014).
Multiple imputation can also be used if one reframes the measurement error problem as a missing
data problem (Little, 1988). Multiple imputation for measurement error is conceptually similar to
regression calibration but uses multiple imputation of the true covariate, as opposed to a single
imputation based on the estimated regression relationship, to capture uncertainty in the predicted
true covariate value (Cole, Chu, and Greenland, 2006).
This paper examines the performance of methods for bias reduction in the context of EHR-based
comparative effectiveness analyses in which an error-prone covariate is included in the estimation of a propensity score. We investigated the scenario where gold-standard covariate data are
available for a validation subset of the population. These methods were evaluated through simulation studies that mimic the general structure of an EHR-based analysis and were also applied to
an analysis of comparative effectiveness of common treatment strategies (e.g., chemotherapy or
immunotherapy) for metastatic bladder cancer (mUC) using EHR data from a national sample of
cancer clinics curated by Flatiron Health. (USFDA, 2018) The overarching objective of this work
is to provide guidance on best practices for accounting for measurement error in propensity scoreadjusted analyses.

2.2. Methods
We consider a scenario in which the objective of the analysis is to estimate the association between
treatment and outcome, accounting for confounders, one of which contains measurement error,
using propensity score adjustment. Several measurement error methods that are commonly applied
to error-prone covariates will be compared. We explore the case where the measurement error
correction methods are applied directly to the estimated propensity score as opposed to the errorprone covariate.
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2.2.1. Notation
Let the full sample be of size N and contain information on X̃, the error-prone covariate(s), Z,
additional covariates measured without error, T , the binary treatment, and Y , the outcome, for
each subject. Let X̃ be a matrix of size N by p, where p is the number of error-prone covariates,
and let Z be a matrix of size N by m, where m is the number of covariates measured without error.
X̃ has the form ωX + , where ω is an unknown scaling factor and  ∼ N (0, σ2 ). The error-prone
covariate, X̃ may be a scalar or a vector of error-prone covariates. We assume we additionally have
access to a validation subset, consisting of a simple random sample of the full sample of size n,
with n ≤ N , that contains information on X, the true covariate(s), X̃, Z, T, and Y for each subject,
denoted XV , X̃V , ZV , T V , and Y V . Therefore, for subjects 1, ..., n we have access to complete
information and for subjects (n + 1), ..., N we are missing at least one of the true covariate values,
X. Note that if n = N the true covariate is available for the full sample and therefore no adjustment
is necessary. The assumption that the validation sample is a simple random sample from the full
sample and therefore has the same conditional distribution of X|T, X̃, Z as the larger sample is
crucial for the adjustment methods discussed below.
We assume that the true data generating model takes the general form

g(E[Y ]) = θ0 + T θ1 + Xθ2 + Zθ3 ,

(2.1)

where θ2 is a p by 1 matrix and θ3 is an m by 1 matrix. and explore performance of alternative
measurement error methods for two link functions, g(x) = x and g(x) = log(x).
To account for confounding of the treatment effect by X and Z, we fit a regression model adjusted
for the logit of the propensity score, referred to as the outcome model,

g(E[Y ]) = β0 + β1 T + β2 logit(e(Q)),

(2.2)

where e(Q) is the propensity score, defined as P (T = 1|Q) and Q = {X, Z}. The outcome model
is presented in scalar form as opposed to the data generating model, which is presented in matrix
form due to the fact that the propensity score reduces the dimensionality of the covariates from p+m
to one. When the propensity score fulfills positivity, strong ignorability, and the stable unit treatment
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value assumption, the propensity score is also a balancing score (Rosenbaum and Rubin, 1983).
The logit of the propensity score is used here because many of the adjustment methods rely on an
assumed linear relationship between the error-prone and true covariate. This assumption is more
likely to be approximately satisfied for the logit transformed propensity score which is unbounded
as compared to the propensity score itself which is constrained to lie in the interval (0,1).
The treatment effect, θ1 , is the estimand of interest that we seek to estimate with β1 . For subjects
that do not have information on X, X̃ can be used in the construction of the propensity score
instead, producing e(Q̃) = P (T = 1|Q̃). In general, e(Q̃) 6= e(Q).
2.2.2. True Propensity Score (TPS)
In the true propensity score model the propensity score is estimated from perfectly measured covariates for all subjects (under the assumption of no unmeasured confounders). This approach is
included as a positive control so that it can be seen how the other methods perform in comparison
to a method using the best possible information for all subjects. In practice, this will not be possible since the true covariate values are not available for all subjects in the observed data set. Let
β̂T P S = β̂1 from the outcome model (equation 2.2).
2.2.3. Error-Prone Propensity Score (EPPS)
Similarly, the error-prone propensity score model is also not an adjustment method, but in contrast
to TPS, EPPS serves as a negative control to which the performance of the other methods may be
compared. Under this approach we fit the model

g(E[Y ]) = β̃0 + β̃1 T + β̃2 logit(e(Q̃))

(2.3)

ˆ
and let β̂EP P S = β̃1 from this model be our estimate of β1 .
2.2.4. Propensity Score Regression Calibration (RC)
Regression calibration assumes that an error-prone covariate available for the full sample is related to the true covariate and that this relationship can be described by a linear model (Carroll
et al., 2006; Rosner, Spiegelman, and Willett, 1990). This allows the true value to be predicted
based on the error-prone value. We consider application of the regression calibration approach to
a propensity score.
An estimate for the logit propensity score using the true covariate values is regressed on an esti-
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mate for the logit propensity score based on error-prone covariates in the validation subset. Specifically, we assume

E[logit(e(QV ))|T V , logit(e(Q̃V ))] = α0V + α1V T V + α2V logit(e(Q̃V )).

(2.4)

Fitted values for the the logit of the propensity score from this model are then included as a covariate in the outcome model producing an estimate for the treatment effect, β̂RC . It can be shown
ˆ
ˆ
that β̂RC = β̃1 − (α̂1V /α̂2V )β̃2 (Carroll et al., 2006; Rosner, Spiegelman, and Willett, 1990). The vari V
d β̂RC ) = Var(β̃ˆ1 ) + Var α̂V1 Var(β̃ˆ2 ) +
ance of the regression calibration estimator has the form Var(
α̂2
 V
h Vi
 h Vi

α̂1
α̂1
α̂1
ˆ 2
ˆ
ˆ ˆ
d β̂RC ) can
E[β̃2 ] Var α̂V + E α̂V Var(β̃2 ) − 2 E α̂V Cov(β̃1 , β̃2 ) . The specific derivation of Var(
2

2

2

be found in the supplemental materials and the general derivation in matrix form can be found in
Rosner et al. (Rosner, Spiegelman, and Willett, 1990).
2.2.5. Efficient Regression Calibration (ERC)
Efficient regression calibration uses a weighted combination of two estimates of β1 : β̂RC and the
estimate of the treatment effect in the validation subset only, β̂1V , estimated by the following model
(Spiegelman, Carroll, and Kipnis, 2001).

g(E[Y V ]) = β0V + β1V T V + β2V logit(e(QV )).

(2.5)

The efficient regression calibration estimate of β1 is denoted by β̂ERC = wRC β̂RC + (1 − wRC )β̂1V ,
where
d β̂RC )−1 [Var(
d β̂RC )−1 + Var(
d β̂ V )−1 ]−1 .
wRC = Var(
1

d β̂RC )−1 + Var(
d β̂ V )−1 ]−1 . Spiegelman, et al. show that these weights
Additionally, Var(β̂ERC ) = [Var(
1
result in the most efficient estimator in the class of unbiased estimators (Spiegelman, Carroll, and
Kipnis, 2001).
2.2.6. Monte Carlo Regression Calibration (MCRC)
Multiple imputation for measurement error, herein referred to as Monte Carlo regression calibration
(MCRC), is similar to regression calibration but takes into account the uncertainty in the relationship
between the true and observed covariate values (Cole, Chu, and Greenland, 2006). Just as in
regression calibration the relationship between the logit of the propensity score estimated from the
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true covariate values and the logit of the propensity score estimated from the observed covariate
values is obtained via a regression of the former on the latter and the treatment assignment in
the validation subset (equation 2.4). However, instead of using fitted values from this model as
covariates in the outcome model, the variance-covariance matrix for the regression coefficients is
used to generate k draws, e.g. k = 10, from the sampling distribution for the coefficients (Cole,
Chu, and Greenland, 2006).
The predicted values for the logit of the propensity score estimated from the true covariate values
are calculated for each sample from the distribution of the coefficients,
(d)

(d)

(d)

[ (d) = α̂ + α̂ T + α̂ logit(e(Q̃)), (d) = 1, . . . , k
logit(e(Q))
0
1
2

The outcome model (equation 2.6) is fit k times, once for each of the k data sets.
(d)

(d)

(d)

[ (d) , (d) = 1, . . . , k.
g(E[Y ]) = β0 + β1 T + β2 logit(e(Q))

(2.6)

Pk
(d)
The MCRC estimator is given by β̂M CRC = k1 d=1 β̂1 , where β̂1d is the estimate for β1 obtained in



Pk
(d)
1
2
d β̂M CRC ) = 1 Pk V ar(β̂ (d) )+ 1+ 1
the dth sample, and Var(
(
β̂
−
β̂
)
(Cole,
M
CRC
1
d=1
d=1 1
k
k
k−1
Chu, and Greenland, 2006). The MCRC approach produces an estimated treatment effect that has
been calibrated to account for error in the error-prone covariate and that also takes into account the
uncertainty introduced by estimating the coefficients in the regression calibration model.
2.2.7. Multiple Imputation of Propensity Scores (MIPS)
Multiple imputation of propensity scores transforms the measurement error problem for the logit
of the error-prone propensity score into a missing data problem. Under this approach, we impute
the logit of the true propensity score using information on the relationship between the logit of the
error-prone propensity score, the logit of the true propensity score, the treatment indicator, and the
outcome derived from the validation subset. In numerical examples below, multiple imputation is
performed by predictive mean matching (PMM) (Little, 1988). PMM has some advantages over
other imputation methods such as ensuring that all imputed values are plausible and performing
well even if the structural form of the model used by PMM does not fit well (Buuren and GroothuisOudshoorn, 2011).
The logit of the propensity score is imputed for each subject k times and the estimate in the dth
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\
imputed sample is denoted logit(e(Q))

(d)

, d = 1, . . . , k. The outcome model (equation 2.6) is fit

k times, and the MIPS estimator and its variance are obtained by combining estimates across
imputations, just as for the MCRC estimator.
2.2.8. Two-Stage Calibration (TSC)
Two-stage calibration uses two models already introduced, the relationship between the logit of
the propensity score based on the error-prone covariates and the outcome in the entire sample
(equation 2.3) and the relationship between the logit of the propensity score based on the true
value of the covariates and the outcome in the validation subset only (equation 2.5) in addition to
the relationship between the logit of the propensity score based on the error-prone covariates and
the outcome in the validation subset only,

g(E[Y V ]) = β̃0V + β̃1V T V + β̃2V logit(e(Q̃V )).

The two-stage calibration estimator utilizes the difference between the treatment effect in the valiˆ
dation subset when the error-prone covariate is used, β̃1V , and when the true covariate is used, β̂1V ,
as a measure of how different the treatment effect is likely to be between these two versions of the
covariate in the main sample.
The two-stage calibration estimator is given by
ˆ
ˆ d V ˆV
ˆ d ˆV
ˆ
β̂T SC = β̂1V − (β̃1V − β̃1 )Cov(
β̂1 , β̃1 − β̃1 )Var(
β̃1 − β̃1 )−1 and
d β̂ V , β̃ˆV − β̃ˆ1 )2 Var(
d β̂ V ) − Cov(
d β̃ˆV − β̃ˆ1 )−1 (Lin and Chen, 2014).
Var(β̂T SC ) = Var(
1
1
1
1
2.2.9. Directly adjusting for covariate measurement error
Adjustment of the regression analysis to reduce bias due to the error-prone covariate can be carried
out at two different stages in the analysis. An intuitive option is to directly adjust the error-prone covariate using the above approaches and then estimate the propensity score based on the adjusted
covariate. This method is appealing because the error-prone covariate is corrected to more closely
resemble the true covariate, and then analysis is carried out using a standard propensity score
adjustment. However, this method does not provide any benefit relative to using the error-prone
covariate alone. This can be seen by relating the error-prone covariate, X̃, to the true covariate
value, X, and the other observed covariates, Z, for the validation subset.
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X̂ = E[X|X̃, Z] = η0V + η1V X̃ V + η2V ZV

Following the regression calibration approach, X̂ can be substituted into the logistic regression for
treatment assignment as follows:

logit(E[T |X, Z])

= ν0 + ν1 X̂ + ν2 Z
= ν0 + ν1 (η0V + η1V X̃ + η2V Z) + ν2 Z
=

(ν0 + ν1 η0V ) + ν1 η1V X̃ + (ν1 η2V + ν2 )Z.

If we had simply performed a logistic regression for the treatment regressed on the error-prone
covariate and other covariates, we would have

logit(E[T |X̃, Z]) = δ0 + δ1 X̃ + δ2 Z

implying that δ0 = ν0 + ν1 η0V , δ1 = ν1 η1V , and δ2 = ν1 η2V + ν2 and therefore no new information for
the treatment assignment model was gained by using the error-prone covariate after adjustment to
more closely resemble the true covariate value.
The alternative is to estimate the propensity score based on the error-prone covariate and then use
an adjustment method to correct the imperfect propensity score itself. This is the basis of our work
presented above.

2.3. Simulation Study
We conducted a simulation study to investigate the relative bias and efficiency of the alternative
measurement error methods described in the previous section under a range of scenarios resembling those likely to be encountered in real-world studies based on EHR data. Data were simulated
for four covariates (Z) in addition to the true covariate (X) and the error-prone covariate (X̃).
Two different outcome models were investigated in the simulation study, a log linear model and a linear model. We simulated error from six different scenarios (Table 2.2). Additionally, we investigated
four scenarios for the size of the full sample and validation sample (n =50, N =1,000; n =100,
N =1,000; n =50, N =10,000; and n =100, N =10,000). Three different strengths of confounding
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between the true covariate value and the treatment assignment were explored. Ten imputations
were used in MCRC and MIPS methods. Relationships among the simulated variables and the
complete set of distributions and parameter values used to simulate data along with examples of
EHR-derived covariates used to motivate the simulation study are provided in Table 2.1.
Each simulation scenario was repeated 10,000 times. We report bias, 95% confidence interval coverage probabilities, empirical standard errors, and model-based standard errors for each method
and scenario.
Table 2.1: Data generation scheme and parameter values used for simulation study.
Variable

Distribution

Analogous EHR Variable

Z1

Uniform(30, 60)

Age

Z2

Bernoulli(0.8)

Gender

Z3

Bernoulli(0.6)

Race

Z4

Bernoulli(0.3)

Medications

X

X = 8 + 0.025Z1 + ;  ∼ N (0, 1)

X̃

ωX + N (0, σ2 > 0)

1-year Comorbidity Score
1-month Comorbidity Score

logit(P (T = 1)) = λi − 0.01Z1 + 0.2Z2
T

−0.05Z3 − 0.25Z4 + ηi X; i = 1, 2, 3

Immunotherapy

λ = {−0.21, −4, −6.6}; η = {ln(1.1), ln(1.5), ln(2)}
Y1

log(P (Y1 = 1)) = −9.9 + 0.005Z1 − 0.025Z2

6-month Mortality

−0.05Z3 + 0.075Z4 + ln(2.2)X + 0.22T
Y2

Y2 = 100 + Z1 − 2Z2 − 3Z3 + Z4 + 4X + 10T

Albumin Lab Value

Table 2.2: Error structures for constructing the error-prone covariate from the true covariate for the
simulation study. Error structures A-C are non-differential, while error structures D-F are differential
with respect to treatment assignment.
Error

Treated Subjects

Control Subjects

Structure

ω

σ2

ω

σ2

A

1

1

1

1

B

0.8

0

0.8

0

C

0.8

1

0.8

1

D

0.8

0

0.8

1

E

0.8

1

0.9

1

F

0.8

0

0.9

1

2.3.1. Simulation Results
The five methods (RC, ERC, MCRC, MIPS, and TSC), along with EPPS as the negative control,
were applied under 144 scenarios arising from the factorial combination of the two link functions,
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two main sample sizes, two validation subset sizes, three values for the magnitude of the regression
parameter relating the true covariate value to treatment assignment, and six error structures. Results for the other three main sample size and validation subset combinations were nearly identical
to the results for N = 10,000, n = 100 and thus are not presented.
Continuous Outcome
In the scenario with a continuous outcome and a validation subsample of 100 with a full sample of
size 10,000 the overall pattern of relative performance of the methods was consistent across values
for the strength of confounding (Figure 2.1).
Under error structure A (ω = 0,  = 1) all five methods had low bias, with MIPS and TSC having the
smallest bias across confounding levels. Notably, TSC was less efficient than the other methods
(Table B.1). Additionally, the regression calibration-based methods (RC, ERC, MCRC) achieved
near-nominal coverage probabilities (∼ 90% - 95%) while the coverage probabilities for MIPS and
TSC were inflated for weak confounding, approximately nominal for moderate confounding, and
below nominal for strong confounding (Table 2.3).
The performance of the five methods were comparable to one another and to EPPS when the
error-prone covariate was a percentage of the true covariate (error structure B), though here MIPS
was less efficient than the other methods (Table B.1). In the case of error structure B, even EPPS
had minimal bias and greater than 95% coverage, which matched the larger than nominal coverage
seen by all the other methods across all three levels of confounding (Table 2.3).
When the error-prone covariate was a percentage of the true covariate plus some random error
(error structure C), the results were nearly identical to those of error structure A (Figure 2.1).
Under error structure D (treatment-dependent difference in ) bias was similar to the results seen
under error structures A and C though the regression calibration-based methods (RC, ERC, MCRC)
did have residual bias in the weak confounding case and as a result had confidence intervals with
less than nominal coverage in the weak and moderate confounding cases (Figure 2.1, Table 2.3).
The two remaining differential error structures, E (treatment-dependent difference in ω) and F
(treatment-dependent difference in  and ω) displayed more notable differences in bias across methods while their results were remarkably similar to one another. In both of these error structures
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EPPS had high bias regardless of the strength of confounding (Figure 2.1). The three regression calibration-based methods over-corrected the estimate given by EPPS, though the absolute
bias was less than that for EPPS. Additionally, the empirical standard errors for the regression
calibration-based methods were very large in the weak confounding case (Figure 2.1). Both TSC
and MIPS performed well across all levels of confounding, having both better point estimates and
smaller intervals than the other adjustment methods (Figure 2.1). However, while the regression
calibration-based methods and MIPS were able to achieve near nominal coverage in the weak and
moderate confounding cases, TSC had low coverage (Table 2.3). Interestingly, in the strong confounding case the coverage of the regression calibration-based methods was poor and the best
coverage was by MIPS and TSC, although this was not due to an inflated variance estimate for
MIPS (Table B.1).
Additionally, EPPS only had nominal coverage under error structure B for all three levels of confounding and additionally for error structures A and C for weak confounding (Table 2.3).
Additional simulations were conducted where both the true data-generating model and the propensity score model contained an interaction between X and Z. The results of these simulations
were largely similar to the results presented above with the following differences. Nearly all the
methods had poorer coverage than the results presented above and all the methods with the exception of TSC had larger model-based and empirical standard errors (Supplemental Figure B.1,
Supplemental Tables B.3,B.5).
Binary Outcome
In the scenario with a binary outcome and a validation sample of 100 sampled from a full sample of
size 10,000 the overall pattern of relative performance of the methods was consistent across values
for the strength of confounding (Figure 2.2).
Under error structure A (ω = 0,  = 1) all five methods had low bias, with MIPS and TSC having the
smallest bias under weak confounding and TSC along with the regression calibration-based methods having the smallest bias under strong confounding (Figure 2.1). Confidence interval coverage
was approximately nominal for all adjustment methods under weak confounding. Coverage was
approximately nominal for the regression calibration-based methods under moderate and strong
confounding, while MIPS and TSC had slightly lower coverage (Table 2.4). Additionally, TSC and
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MIPS were less efficient than the other methods (Table B.2).
As seen in the continuous outcome case the performance of the five methods was extremely similar
under error structure B, and MIPS also had larger confidence intervals than the other methods
(Table B.2). In the case of error structure B, even EPPS had minimal bias and over 95% coverage,
which matched the larger than nominal coverage seen by all the other methods across all three
levels of confounding (Table 2.4).
Also similar to the continuous outcome scenario, the binary outcome scenario had nearly identical
results for error structure C and error structure A (Figure 2.2).
Under error structure D (treatment-dependent difference in ) bias was similar to the results seen
under error structures A and C though the regression calibration-based methods (RC, ERC, MCRC)
did have residual bias in the weak confounding case and as a result have confidence intervals with
less than nominal coverage in the weak and moderate confounding cases (Figure 2.2, Table 2.4).
The two remaining differential error structures, E (treatment-dependent difference in ω) and F
(treatment-dependent difference in  and ω) displayed more notable differences in bias across
methods and again their results were remarkably similar to one another. In both of these error
structures, EPPS had high bias regardless of the strength of confounding (Figure 2.2). The three
regression calibration-based methods over-corrected the estimate given by EPPS, though the absolute bias was less than that for EPPS. Additionally, the empirical standard errors for the regression
calibration-based methods were very large in the weak confounding case (Figure 2.2). Both TSC
and MIPS perform well across all levels of confounding, having both better point estimates and
smaller intervals than the other adjustment methods (Figure 2.2). However, while the regression
calibration-based methods and MIPS were able to achieve near nominal coverage in the weak and
moderate confounding cases, TSC had low coverage (Table 2.4).
Similar to the continuous outcome scenarios, EPPS only had nominal coverage under error structure B for all three levels of confounding and additionally for error structures A and C for weak
confounding (Table 2.4).
Additional simulations were conducted where both the true data-generating model and the propensity score model contained an interaction between X and Z. The results of these simula-
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tions had some important differences from the simulation results presented above. The regression
calibration-based methods (RC, ERC, MCRC) had considerably more bias across all confounding strengths and error structures (Supplemental Figure B.2). Additionally, both MIPS and TSC had
much larger variability in the amount of bias present than the regression calibration-based methods.
Furthermore, the regression calibration-based methods had much poorer coverage than the results
presented above, while MIPS and TSC experienced only a small decrease in coverage probabilities
(Supplemental Table B.4). Finally, although the model-based and empirical standard errors were
similar for the regression calibration-based methods, MIPS and TSC have larger standard errors
relative to the main results (Supplemental Table B.6).

Figure 2.1: Bias for the continuous outcome (true value = 10) with validation size 100 and full
sample size 10,000 over three strengths of confounding and six error structures. Intervals displayed
are from the 2.5 percentile to 97.5 percentile of the replications with less than 500% bias out of
10,000 total replications.
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Figure 2.2: Bias for the binary outcome (true value = 0.22) with validation size 100 and full sample
size 10,000 over three different amounts of confounding and six different error structures. Intervals
displayed are from the 2.5 percentile to 97.5 percentile of the replications with less than 500% bias
out of 10,000 total replications.
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Table 2.3: 95% confidence interval coverage probabilities of valid sim-Table 2.4: 95% confidence interval coverage probabilities of valid simulations with continuous outcome, validation size 100, and full sampleulations with binary outcome, validation size 100, and full sample size
size 10,000
10,000
Confounding

Error

EPPS

RC

ERC

MCRC

MIPS

TSC

97.15%

92.05%

91.12%

90.87%

99.36%

99.35%

Confounding

Structure
A

Error

EPPS

RC

ERC

MCRC

MIPS

TSC

A

92.46%

93.49%

93.56%

93.41%

96.83%

94.79%

Structure

B

100%

99.98%

99.96%

99.95%

97.52%

99.96%

B

97.51%

97.39%

97.14%

97.39%

94.87%

95.36%

Weak

C

93.23%

88.89%

87.54%

87.35%

99.34%

99.12%

Weak

C

89.31%

90.88%

90.82%

90.82%

96.77%

94.94%

Confounding

D

28.9%

81.98%

80.89%

79.64%

98.38%

97.47%

Confounding

D

60.26%

64.51%

65.18%

65.66%

96.02%

94.84%

E

0%

98.38%

94.39%

97.1%

97.22%

84.36%

E

0%

99.53%

98.42%

98.16%

97.76%

80.26%
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Figure 2.3: DAG describing relationship among variables in the Flatiron Health mUC study; blue
indicates only observed in validation sample and black indicates observed for all. ELIX is the
weighted Elixhauser comorbidity score.

2.4. Immunotherapy vs Chemotherapy for Metastatic Urothelial Cancer
The objective of this analysis was to illustrate the performance of alternative statistical methods
for measurement error applied to a propensity score estimated using an error-prone covariate in
the specific context of a real-world analysis of EHR-derived data. We analyzed data from Flatiron
Health database, a nationwide EHR-derived de-identified database consisting of data from over 265
cancer clinics including over 2 million active U.S. cancer patients available for analysis (Abernethy et
al., 2017; Berger et al., 2016; Curtis et al., 2018; Miksad and Abernethy, 2018; Presley et al., 2018).
We compared the effectiveness of carboplatin-based chemotherapy compared to immunotherapy
with checkpoint inhibitors via the binary outcome of 6-month mortality in a sample of patients with
metastatic bladder carcinoma (mUC) using propensity score adjustment to account for systematic
differences between chemotherapy and immunotherapy initiators.
In the context of comparative effectiveness of immunotherapy and chemotherapy for treatment of
mUC, the overall health of the patient, as assessed via a comorbidity score, is a key confounder
to include in the propensity score. Lin, et al. showed that comorbidity distributions differ between
patients with low versus high proportions of their visit information captured in the EHR (Joshua Lin
et al., 2017; Lin et al., 2018). It is thus likely that comorbidity scores for some patients will not reflect
the true degree of comorbid disease burden in these patients and that this error could be differential
according to the intensity of the patient’s interaction with the healthcare system. We constructed the
Elixhauser comorbidity score based on one year of EHR data prior to the start of treatment which
we considered the “true” comorbidity score (Elixhauser et al., 1998). Two different error-prone
versions of this comorbidity score were artificially constructed by the addition of error to illustrate
the case where patients vary in the amount of comorbidity information captured in their EHR, one
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non-differential and one differential. In the non-differential case, we introduced error with structure
of ω = 0.25, σ = 4.5, and in the differential case we introduced error with ω = 0.9, σ = 0.5 for
patients on immunotherapy and ω = 0.3, σ = 4.5 for patients on chemotherapy. We assumed that
a validation sample of 100 patients was available for whom information on the true propensity score
was available. All other covariates included in the propensity score (age, gender, race/ethnicity, calendar year, primary site of cancer, smoking status, opioid prescriptions, and steroid prescriptions)
were assumed to be measured without error (Figure 2.3). The propensity score was estimated
by regressing treatment (immunotherapy or chemotherapy) on all of the aforementioned variables
using logistic regression.
The study sample included patients with mUC who began first-line therapy with carboplatin-based
chemotherapy or immunotherapy between January 1, 2011 and July 31, 2018. Patients on therapies that combined immunotherapy and chemotherapies, contained clinical trial drugs, included
cisplatin, or included non-chemotherapy based drugs were excluded from the sample. Patients
starting treatment after July 31, 2018 were excluded to allow for all patients to have at least six
months of followup for the outcome of six-month mortality. Information about opioid and steroid
prescriptions were collected for the two-month period prior to treatment start. This resulted in a
cohort size of 2187 patients, 1600 of whom were treated with carboplatin-based chemotherapy and
587 of whom were treated with immunotherapy (Table 2.5).
2.4.1. Immunotherapy vs Chemotherapy for Metastatic Urothelial Cancer Results
The relative risk of death in the first six months after start of treatment in patients on immunotherapy as compared to patients on carboplatin-based chemotherapy was 1.42 (95% CI: 1.20-1.68)
using the true propensity score for all patients to account for confounding (Table 2.6). Under nondifferential error, several point estimates from the adjustment methods were very similar to one
another, however ERC was able to improve upon EPPS in this scenario. Both MIPS and TSC
over-corrected as compared to EPPS, providing point estimates smaller than that of TPS though
with larger absolute bias than EPPS. (Table 2.6). Under differential error, ERC and TSC had point
estimates closest to the true propensity score method, both with estimates of 1.43, compared to the
truth of 1.42. However, TSC again had a tighter confidence interval around this estimate than TPS,
which indicates an artificially high level of precision. MIPS had an estimate with slightly larger bias
than ERC and a larger confidence interval than that obtained with ERC, demonstrating the loss of
efficiency when the MIPS estimator is used. Further, the other two regression calibration-based
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Table 2.5: Characteristics of patients in the Flatiron Health mUC cohort by treatment type.
Carboplatin-Based

Immunotherapy

Chemotherapy
N = 1600

N = 587

Age, mean (SD)

72.56 (8.48)

74.74 (8.75)

Gender, N (% Male)

1171 (73.2)

427 (72.7)

White

1213 (75.8)

437 (74.4)

Asian

23 ( 1.4)

4 ( 0.7)

Black or African American

75 ( 4.7)

21 ( 3.6)

Hispanic or Latino

71 ( 4.4)

23 ( 3.9)

Other Race

99 ( 6.2)

35 ( 6.0)

Unknown

119 ( 7.4)

67 (11.4)

2011

110 ( 6.9)

0 ( 0.0)

2012

165 (10.3)

0 ( 0.0)

Baseline

2013

224 (14.0)

0 ( 0.0)

Year

2014

238 (14.9)

0 ( 0.0)

N (%)

2015

283 (17.7)

8 ( 1.4)

2016

308 (19.2)

101 (17.2)

2017

195 (12.2)

283 (48.2)

2018

77 ( 4.8)

195 (33.2)

Bladder

1185 (74.1)

444 (75.6)

Renal Pelvis

263 (16.4)

75 (12.8)

Ureter

140 ( 8.8)

65 (11.1)

Urethra

12 ( 0.8)

3 ( 0.5)

History of smoking

1145 (71.6)

434 (73.9)

Status

No history of smoking

419 (26.2)

147 (25.0)

N (%)

Unknown/not documented

36 ( 2.2)

6 ( 1.0)

0.90 (2.67)

1.86 (4.03)

Race/
Ethnicity
N (%)

Primary
Site
N (%)

Smoking

1 year comorbidity score, mean (SD)
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estimates (RC and MCRC) provided estimates that were less biased than EPPS (Table 2.6).
Table 2.6: Relative risk of 6-month mortality and 95% confidence intervals (CI) for patients on immunotherapy compared to carboplatin-based chemotherapy under differential error (left) and nondifferential error (right) in a confounder. LB = lower bound, UB = upper bound

TPS

Relative Risk

95% CI LB

95% CI UB

1.42

1.20

1.68

Differential Error
Relative

95% CI

Non-Differential Error
Relative

95% CI

Risk

LB

UB

Risk

LB

UB

EPPS

1.47

1.24

1.73

1.45

1.23

1.71

RC

1.46

1.24

1.73

1.45

1.22

1.71

ERC

1.43

1.21

1.68

1.43

1.21

1.69

MCRC

1.46

1.24

1.73

1.45

1.22

1.71

MIPS

1.39

1.11

1.73

1.30

1.07

1.57

TSC

1.43

1.24

1.66

1.37

1.19

1.58

2.5. Discussion
Error in confounder variables presents a particularly serious challenge to the validity of EHR-based
research. Prior research has shown that the use of error-prone covariates results in biased treatment effect estimates due to residual confounding (Carroll et al., 2006; Guo, Little, and McConnell,
2012; Rosner, Spiegelman, and Willett, 1990). Our simulation studies explored the effect of study
sample size, validation subset size, degree of confounding, and error structure for both continuous
and binary outcomes on five different methods for correcting measurement error.
The method that was found to perform the best for continuous outcomes was MIPS due to its very
small bias across all error scenarios, its smaller standard errors, and its nominal or near nominal
coverage probabilities. Two-stage calibration was consistently less efficient than MIPS though it
often had similar bias to MIPS, which makes it a less reliable adjustment method. The regression
calibration-based methods had consistently large bias with relatively small standard errors, indicating their undesirable high certainty about a biased result as evidenced by low coverage probabilities. The regression calibration-based methods (RC, ERC, and MCRC) had considerable bias
combined with extremely low coverage probabilities in two of the differential error scenarios, which
makes them less suitable for continuous outcomes.
The recommendation of MIPS holds when both the data-generating model and the propensity score
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model both contain an interaction between X and Z.
On the other hand, the methods that performed the best for binary outcomes were the regression
calibration-based methods (RC, ERC, and MCRC). These methods had very small biases across
the different error structures and achieved nearly perfect nominal coverage while having reasonably
sized standard errors. Both MIPS and TSC performed well in the binary outcome scenario, having
slightly smaller bias than the regression calibration-based methods though this was mitigated by
the combination of poorer coverage and less efficient estimation for both MIPS and TSC.
In the scenario with an interaction between X and Z in both the data-generating model and the
propensity score model, the greatly reduced bias and greater coverage probabilities as compared
to the regression calibration-based methods outweighs the larger standard errors seen in MIPS
and TSC. The performance of MIPS and TSC are quite comparable to one another across the
metrics mentioned, so either MIPS or TSC is recommended when an interaction term between an
error-prone and correctly-measured covariate is present.
Stürmer, et al. previously evaluated the performance of regression calibration applied to an errorprone propensity score. Their evaluation of “propensity score calibration” differed from that considered here in several ways. First, they focused on error in a propensity score arising due to omitted
variables rather than error-prone covariates (Sturmer et al., 2005, 2007). Our method examines
the scenario where the same set of covariates are available for the full and validation samples, but
the values are known to be error-prone for most of the subjects and only a subset have data on
the error-prone and true covariates. Additionally, Stürmer, et al. performed regression calibration
on the untransformed propensity score (Sturmer et al., 2005, 2007). We found that the relationship
between two propensity scores is rarely linear, instead often following an “s”-shaped relationship
due to the truncated range of the propensity score. Therefore, we carried out measurement error
correction methods on the propensity score transformed to the log odds scale. Despite these differences, our findings support those of Stürmer, et al., that regression calibration on a propensity
score can be a useful bias-correction method. (Sturmer et al., 2005, 2007).
Additionally, Lin and Chen previously evaluated the performance of their two-stage calibration
method in the context of propensity scores (Lin and Chen, 2014). Their evaluation of TSC was
similar to our exploration, with the distinction that they used either the untransformed propensity
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score or a spline of the propensity score in the model as opposed to the logit of the propensity
score (Lin and Chen, 2014). Lin and Chen only compared TSC to RC, and found that the point
estimates were less biased using TSC than RC, which supports our conclusions (Lin and Chen,
2014). However, the model-based standard errors that Lin and Chen obtained for each simulation
scenario were very similar between TSC and RC, while in the scenarios we investigated TSC was
substantially more efficient than RC (Lin and Chen, 2014).
Hong, et al. explored the relative performance of calibration methods when more than one covariate
is error-prone and how the performance varies when the error-prone covariates are either highly
correlated or have a low correlation (Hong et al., 2019). This has not yet been explored when
the covariates are used to estimate a propensity score. This represents an interesting direction
for future work as measurement error correction for a single adjustment variable, such as the propensity score, may be easier to implement than adjustment for multiple and potentially correlated
covariates.
A limitation of the work presented here is that all compared methods rely on a validation sample
that is a simple random sample of the full study population. Throughout our simulation study,
a simple random sample was taken in order to form our validation subset. For low prevalence
exposure variables, this is an unrealistic sampling strategy because few or no exposed individuals
might be encountered in a small simple random sample. In the EHR literature, validation sampling
is often carried out conditional on the surrogate measure itself. Additional research is needed to
explore measurement error correction methods in the context of a validation sample that is drawn
conditional on the value of the error-prone covariate.
In conclusion, bias induced by measurement error is not mitigated by the use of propensity scores.
Additionally, while many of the methods investigated perform well in the case of non-differential
error, the true error model is unlikely to be known and therefore methods that can accommodate
differential error should be used in practice. Using appropriate analytic methods to address error in
EHR-derived covariates is key to obtaining valid results from these data sources.
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CHAPTER 3
C OMBINING R EAL -W ORLD

AND

R ANDOMIZED C ONTROL T RIAL DATA U SING

DATA -A DAPTIVE W EIGHTING

VIA THE

O N -T RIAL S CORE

3.1. Introduction
Randomized clinical trials are the gold-standard for testing a new treatment though there can be
some potential disadvantages to running a traditional clinical trial. Clinical trials for rare diseases
can take a long time to accrue patients due to the rarity of the disease, which makes the clinical trial
and drug approval process take longer. Additionally, if a prior Phase II trial has shown superiority
of the new treatment over the standard treatment, it may not be ethical to randomize patients in
a 1:1 ratio, rather it may be preferred to use a 2:1 or 3:1 ratio favoring the intervention over the
standard-of-care. This can result in lower power and the inability to detect an effect even if one truly
exists.
It is therefore appealing to consider combining clinical trial data on patients receiving a novel treatment with data on patients receiving the control therapy derived from electronic health records
(EHR) (Ventz et al., 2019). The appeal of including external patients receiving the standard-of-care
is that it reduces or even completely eliminates the need to randomize patients to a control arm
in the current trial (Schmidli et al., 2020). In a trial with an external control arm, all data on the
standard-of-care is derived from EHR, while, in a hybrid control arm external patients receiving
the standard-of-care from an EHR are combined with randomized trial patients in the control arm
(Burcu et al., 2020).
Electronic health records (EHR) contain a vast amount of data that can be relatively easily leveraged
for research. These data are by nature observational, and, as such, there are a few key features of
EHR data that are worth noting. First, EHR were developed for clinical care and billing purposes.
Therefore, some of the information that researchers may be interested in may not be collected or
may be contained in narrative text notes, which are difficult to analyze. Furthermore, the healthcare
system in the United States, as well as in many other countries, is fragmented such that a patient’s
medical records may be spread across the databases of multiple healthcare systems, which can
result in an incomplete or inadequate picture of a patient’s health when relying on data from an
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individual EHR database.
Though conducting research with EHR data has distinct challenges, approaches have been developed to make beneficial use of this data source.
In 1976, Pocock proposed a method to combine randomized patients receiving the standard-of-care
from historical clinical trials with intervention arm patients from a new trial to address the fact that
many studies of the day examining the efficacy of a new treatment did not contain a randomized
control arm, which made it difficult to draw causal conclusions (Pocock, 1976). The approach
represents a hybrid control arm combining patients randomized to the trial control arm with patients
from the control arm of a historical trial. Pocock proposed six criteria for evaluating what constitutes
an acceptable historical control arm as well as how much weight to assign to historical control
patients relative to randomized control patients (Pocock, 1976).
Pocock’s six criteria can also be applied to the use of EHR data to construct the hybrid control
arm of a trial with varying success. These six proposed guidelines along with considerations for
application to an EHR-derived hybrid control arm are presented below:
1. “Such a group must have received a precisely defined standard treatment which must be the
same as the treatment for the randomized controls.” Patients derived from EHR data can be
selected such that they are receiving the same primary treatment as the randomized trial
control patients. However, supportive care and the care environment may differ between the
trial and routine clinical practice.
2. “The group must have been part of a recent clinical study which contained the same requirements for patient eligibility.” By definition the EHR patients are not part of a recent clinical trial
but efforts should be made to identify an EHR-derived cohort using eligibility criteria as similar
to the trial as possible. Due to limitations of EHR data capture, it may be difficult to apply all
clinical trial inclusion/exclusion criteria (Ramsey et al., 2020).
3. “The methods of treatment evaluation must be the same.” This criterion may or may not be
met, depending on the outcome and method of outcome ascertainment used in the trial. While
it is imperative for the outcome measure to be the same, outcome ascertainment may differ
between the trial and EHR data capture. For example, even an outcome such as death can
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have sensitivity between 30% and 90%, meaning that there are deaths that are not recorded
in the EHR (Carrigan et al., 2019).
4. “The distributions of important patient characteristics in the group should be comparable with
those in the new trial.” Patients receiving the control treatment in routine care may differ in
many ways from patients participating in a trial. The requirement of the same distribution
of patient characteristics in the EHR patient pool as the trial patients is possible but highly
unlikely to be exact; similarity, however, should be striven for.
5. “The previous study must have been performed in the same organization with largely the
same clinical investigators.” This criterion is not able to be met by definition.
6. “There must be no other indications leading one to expect differing results between the randomized and historical controls.” This is unlikely to be met completely due to many differences between real-world and clinical trial care. However, if the EHR data is contemporaneous with the current trial it is reasonable to assume that care received by the EHR patients is
similar to the care received by the trial control patients.
Overall, if an EHR cohort can be constructed such that the patients are contemporaneous with the
clinical trial, the same inclusion/exclusion criteria are applied to ensure comparable patient populations are under study, EHR control patients receive the same treatment as the clinical trial control
arm patients, and the outcome and method of outcome ascertainment are as similar between EHR
data capture and the trial as possible, it may be appropriate to use EHR data as part of a hybrid
control arm.
There are several approaches to using external control patients when estimating treatment effects,
including Pocock’s approach which was among the first. Although these methods were developed
in the context of historical controls, where control patients are drawn from a previously conducted
clinical trial, they can also be applied to the case where control patients are drawn from an EHR
database. This does not affect the implementation of the methods, though interpretation must
be made carefully. We assume throughout this paper that only patients in the trial receive the
intervention therapy. Pocock’s method assumes that the parameter of interest is the difference
between the mean outcome in the intervention arm patients and the mean outcome in the standardof-care arm patients in the clinical trial. Pocock’s method also assumes that the true mean value for
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the trial standard-of-care patients follows a normal distribution centered at a weighted sum of the
sample mean of the trial standard-of-care patients and the sample mean of the external standard-ofcare patients, where weights are selected based on the extent to which external standard-of-care
patients are believed to be representative of trial standard-of-care patients and with a standard
deviation also dependent upon these factors (Pocock, 1976).
Chen, et al. introduced a Bayesian approach to estimating the effect of a treatment when using
hybrid control arms that relies on power priors (Chen, Ibrahim, and Shao, 2000; Ibrahim and Chen,
2000). This approach incorporates external standard-of-care arm data with the current trial data by
taking only a fraction of the information from each external standard-of-care patient (Chen, Ibrahim,
and Shao, 2000; Ibrahim and Chen, 2000). The power prior can estimate many different estimands,
including differences in means or proportions, hazard ratios, or odds ratios. In this method, the pool
of external standard-of-care patients is weighted as a whole and the external standard-of-care
patients are assigned anywhere from 0% to 100% of the weight that a current trial participant,
whether intervention or standard-of-care, receives in the final model (Chen, Ibrahim, and Shao,
2000; Ibrahim and Chen, 2000). When α, the weight assigned to external standard-of-care patients,
is 0, the power prior approach is equivalent to using no data from the external standard-of-care
patients, and when α is 1, the power prior approach is the same as fully pooling the external
standard-of-care patients with the current trial data (Chen, Ibrahim, and Shao, 2000; Ibrahim and
Chen, 2000). This method may be more interpretable than Pocock’s method as the amount of
information incorporated is quantified directly through α rather than through a variance parameter
(Chen, Ibrahim, and Shao, 2000; Ibrahim and Chen, 2000). Similar to Pocock’s method, the amount
of information incorporated from the external standard-of-care patients must be prespecified by the
researcher and sensitivity analyses are recommended to determine the robustness of results to
choice of α (Chen, Ibrahim, and Shao, 2000; Ibrahim and Chen, 2000; Pocock, 1976).
Duan and Ye in 2008 (Duan and Ye, 2008) and Neuenschwander, et al. in 2009 (Neuenschwander,
Branson, and Spiegelhalter, 2009) concurrently developed the normalized power prior approach,
which extended the power prior model to estimate α from the data rather than using a prespecified
α (Duan and Ye, 2008; Neuenschwander, Branson, and Spiegelhalter, 2009). The normalized
power prior approach allows for larger weights to be allocated to the external standard-of-care
patients when the external standard-of-care patients are similar in terms of outcome to the current
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trial patients and smaller weights when they are dissimilar (Duan and Ye, 2008; Neuenschwander,
Branson, and Spiegelhalter, 2009).
These earlier methods focused on weighting external standard-of-care patients as a group, whether
the weight is pre-specified or data-driven. More recent extensions have considered individualweighting of external standard-of-care patients based on the similarity of each individual to patients
in the trial standard-of-care arm. One such adaptation of the power prior approach proposes dividing the external standard-of-care patients into subgroups based on their similarity to the trial
patients and assigning a weight to each subgroup based on the commensurability between external patients and trial patients in that subgroup (Wang et al., 2019). Another recently proposed
method uses a modification of the propensity score, called the on-trial score, to create matches
between the external standard-of-care patients and the trial standard-of-care patients in order to
create a hybrid standard-of-care arm consisting of patients most similar to those in the clinical trial
intervention arm (Lin, Gamalo-Siebers, and Tiwari, 2019).
In this paper, we propose a new data-adaptive weighting method that addresses the limitation of
assigning a single weight to the entire group of external standard-of-care patients by assigning
weights to each individual in the external standard-of-care arm based on similarity to trial patients
using the on-trial score. The use of individualized weights helps to account for the fact that patients
included in EHR databases may be more heterogeneous than patients included in clinical trials. The
proposed approach incorporates more information from standard-of-care patients who are more
similar to trial participants than those who are not.
The structure of the paper is as follows: in section 2 we define notation, outline the existing approaches used for hybrid standard-of-care arms and introduce our proposed method for combining
trial standard-of-care patients with external standard-of-care patients. In section 3, simulations are
presented to assess the relative performance of our new method compared to existing methods.
Section 4 applies all methods discussed to a clinical study for patients with metastatic castrationresistant prostate cancer comparing the standard-of-care treatment of prednisone with the new
treatment of abiraterone acetate in conjunction with prednisone with with external standard-of-care
patients from a pseudo EHR, and section 5 provides a summary and discussion.
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3.2. Methods
3.2.1. Notation
We assume the existence of a trial of size NT rial and an external data source, e.g. an EHR
database consisting of patients meeting comparable inclusion/exclusion criteria and receiving the
same treatment as trial standard-of-care arm patients, of size NExternal . Let N = NT rial +
NExternal . Let each patient in each database have information on a set of k covariates, XN xk =
{X1 , X2 , . . . , Xk }. Additionally, let R be an indicator such that Ri takes the value of 1 if the ith
patient is in the external data source and 0 if the ith patient is enrolled in the trial. Similarly, let
T be a treatment indicator such that Ti takes a value of 0 if the ith patient receives the standardof-care and 1 if the ith patient receives the intervention. In our numerical experiments below, we
a have a time to event outcome variable, Y = min(F, C), where F is the time of the event of
interest (failure time), C is the censoring time. Also, let S be a status indicator where Si takes
a value of 1 if Ti < Ci and 0 otherwise. Extensions to outcomes of other variable types follow
directly from the likelihood-based formulation below. We denote the data available for the set of
external standard-of-care patients as D0 = {X, S, Y|Ri = 1}, the set of randomized standard-ofcare patients as DC = {X, S, Y|Ri = 0, Ti = 0}, the set of randomized intervention arm patients
as DT = {X, S, Y|Ri = 0, Ti = 1}, and the set of all trial patients as D = (DT , DC ). We also
let θ denote a target parameter of interest that represents treatment efficacy which could be parameterized as a difference in mean event times or hazard ratios comparing intervention arm and
standard-of-care patients.
Below we summarize existing and proposed approaches to incorporating data from external
standard-of-care patients into an analysis of treatment efficacy.
3.2.2. Existing Approaches to Hybrid Control Trials
Naı̈ve Approaches
Ignoring the external data and using only the current trial data serves as a positive control with
regards to the minimum bias that can be attained when estimating the parameter of interest. In this
method, only the data from the patients enrolled in the trial are analyzed and the patients from the
external data source are left out.
Fully pooling the external data with the trial data serves as a negative control with regards to the
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amount of bias that is likely to occur when estimating the treatment effect. In this case, the external
patients are given the same weight as the trial patients and all external patients are included in the
analysis.
Bayesian Approaches
The power prior (PP) approach combines the external patients with the trial patients such that each
external patient has a weight less than 1 (Ibrahim and Chen, 2000). The power prior approach
assigns the same weight, α, such that 0 < α < 1, to all patients in the external data source and the
value of α is prespecified by the researcher. The power prior approach proposes the following prior
distribution for θ: π(θ|D0 , α) ∝ L (θ|D0 )α π(θ) which yields the following posterior distribution for θ:
π(θ|D0 , D, α) ∝ L (θ|D)[L (θ|D0 )α π(θ)].
The normalized power prior approach (NPP) is similar to the power prior approach except that α
is estimated from the data rather than being pre-specified by the researcher (Duan and Ye, 2008).
The normalized power prior approach specifies a conditional prior for θ given α and a marginal
distribution for α. The normalized power prior approach has the form:

π(θ, α|D0 ) ∝ R

L (θ|D0 )α π(θ)
π(α),
L (θ|D0 )α π(θ)dθ
Θ

which results in the following posterior:

π(θ, α|D0 , D) ∝ L (θ|D)π(θ, α|D0 ) ∝

L (θ|D)L (θ|D0 )α π(θ)π(α)
R
.
L (θ|D0 )α π(θ)dθ
Θ

If π(α) is proper then the normalized power prior will also be proper.
Lin’s Method
Lin’s method uses an on-trial score, similar to a propensity score, where the outcome of interest
is inclusion in the trial to construct a matched set of external standard-of-care patients and weight
their likelihood contribution (Lin, Gamalo-Siebers, and Tiwari, 2019). The on-trial score is estimated
as the probability that a patient is in the clinical trial given their baseline covariates using a logistic
regression model. Next, optimal pair matching is performed using the on-trial score so that each
trial patient receiving the intervention is matched with an external standard-of-care patient. The
selected external standard-of-care patients form a pool from which NT − NC patients are randomly
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drawn so that the augmented trial has a 1:1 ratio of treated to standard-of-care patients. In the
outcome model the external standard-of-care patients are weighted by their on-trial scores while
the trial patients are given a weight of one (Lin, Gamalo-Siebers, and Tiwari, 2019).
3.2.3. Proposed Approach: Data-Adaptive Weighting
In our proposed approach, we define the on-trial score as the probability that the ith patient is
included in the trial given the observed baseline covariates, P (Ri = 0|Xi ) = e(Xi ). To maximize
the similarity between external and randomized standard-of-care patients, we then limit the set
of external standard-of-care patients to the subset with the highest on-trial scores, such that the
number of external standard-of-care patients selected results in a hybrid control arm of the same
size as the intervention arm. By selecting external patients with the highest on-trial scores we
select the subset of external patients that are most similar to the trial patients. Although some
trial patients will have small on-trial scores, in the setting where observed covariates are predictive
of trial membership, the on-trial scores for the trial patients will be left-skewed with the majority
having on-trial scores close to one. Let D0∗ represent data for the subset of D0 with the NDT − NDC
largest on-trial scores. The on-trial scores are then transformed to obtain values for γ̂i such that
PND∗
γ̂i = e(Xi )/(1 − e(Xi )) and standardized such that γ̂i∗ = γ̂i ND∗0 / i=10 γ̂i . The inverse odds weight
is used as we are interested in the average treatment effect on the treated, or in this case, the
average treatment effect for those on-trial. This weighting method assigns all trial patients their full
weight and only up- or down-weights the selected external standard-of-care patients.
Estimation for data-adaptive weighting then uses a prior for θ of the form:
ND∗

π(θ|γ̂ ∗ , D∗0 ) ∝

Y0 
∗
L (θ|D∗0i )γ̂i π(θ),

(3.1)

i=1

which gives the following posterior:
N

π(θ|γ̂

∗

, D∗0 , D)

∗

D
ND
Y

 Y0 
∗
∝
L (θ|Dj )
L (θ|D∗0i )γ̂i π(θ)

j=1

(3.2)

i=1

We note that all patients are used in the estimation of the on-trial score as, assuming trial patients
are randomly assigned to intervention arm, the distribution of baseline covariates is the same for
standard-of-care arm and intervention arm patients. Here the on-trial score is estimated via a
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logistic regression, rather than being jointly estimated with θ. However, the on-trial score may be
estimated using more flexible modeling such as a random forest or ensemble machine learning if
desired.
3.2.4. Estimation
The Bayesian estimation approach for the models presented above, under certain conditions, can
be approximated using a frequentist analog. For example, in the case of the DAW method, when a

∗
non-informative prior is used for θ, the prior for DAW, π(θ|D0 , γ̂ ∗ ) ∝ L (θ|D0 )γ̂i π(θ), is equivalent
∗

to π(θ|D0 , γ̂ ∗ ) ∝ L (θ|D0 )γ̂i . In this case the posterior mode corresponds to the maximum likelihood estimator for a weighted parametric survival model. In this case, estimates from a weighted
Cox proportional hazards model with weights of 1 for trial patients and γ̂ ∗ for selected external
standard-of-care patients will provide similar estimates to the Bayesian estimates with flat priors.
This approach may be preferable to a fully Bayesian estimation approach because of its relative
computational efficiency and insensitivity to prior specification. In numerical experiments below, we
investigate performance of estimation using this weighted Cox approach for all methods described
above.
Our proposed method, data-adaptive weighting (DAW), builds on the power prior approach and
Lin’s approach. While the power prior approach and normalized power prior approach both use the
same α value for all patients, DAW uses individual weights for the external patients depending on
their similarity to the trial patients. Lin’s approach uses individual weights for each of the external
patients. However, the selected external patients are based upon matching on the on-trial score
and selected subjects are directly weighted by the on-trial score.

3.3. Simulation Study
We conducted a simulation study to investigate the bias, efficiency, effective sample size, and type
I error of the existing methods outlined above and the data-adaptive weighting method. Data were
simulated with the objective of generating simulated data resembling a real-world study using trial
data and external standard-of-care data from an EHR database.
Data were simulated for four covariates (X), a real-world indicator (R), a treatment indicator (T ), a
failure time (F ), and a censoring time (C). We simulated data for trials of two different sizes (100,
1000), each with two different randomization ratios of the number of patients in the intervention
arm to the number of patients in the standard-of-care arm (2:1 and 3:1). The number of external
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standard-of-care patients available was equal to the number of trial patients. These values were
selected to mirror real-world scenarios for unbalanced clinical trials and provide enough potential
EHR patients to distinguish between the performance of the various methods. The hazard ratio for
failure for patients in the intervention arm versus randomized standard-of-care patients (treatment
effect) was allowed to take values of 0.5, 0.75, 0.875, and 1. Two different strengths of confounding
of the relationship between baseline covariates and failure were also explored: mild confounding
and strong confounding. We note that these covariates confound the relationship between enrollment in the trial and the outcome because the baseline covariate distribution differs between trial
and external standard-of-care patients. Analyses limited to the trial population are unconfounded
because there is no relationship between trial arm and baseline covariates due to randomization.
Censoring rate was held constant across all simulation scenarios. External standard-of-care patients had censoring times arising from an exponential distribution with rate 0.4 and trial patients
had censoring times arising from an exponential distribution with rate 0.1.
Relationships among the simulated variables and the complete set of distributions and parameter
values used to simulate data, along with examples of EHR-derived covariates used to motivate the
simulation study are provided in Table 3.1.
Table 3.1: Data generation scheme and parameter values used for simulation study.
Variable
X1
X2
X3
X4
T
Yf ailure

Ycensor

Trial Distribution
Bernoulli(0.5)
Bernoulli(0.6)
Normal(60, 5) − 60
Normal(21, 2) − 21
Bernoulli(t), t = {0.67, 0.75}

External Distribution
Bernoulli(0.55)
Bernoulli(0.4)
Normal(60, 10) − 60
Normal(23, 2) − 21
0

Exp[log(η)T + log(β)X]
η = {0.5, 0.75, 0.875, 1}
β=
{(1.25, 0.67, 0.98, 1.06),
.
(2.25, 0.4, 0.93, 1.21)}
Exp(0.1)
Exp(0.4)

Analogous Variable
Gender
College Degree
HDL Cholesterol
BMI
Treatment Indicator
Failure Time

Censoring Time

In numerical examples, the on-trial score was estimated using logistic regression including all baseline covariates as predictors. The covariates (X) were simulated with different distributions dependent on trial membership status (R) rather than having R be simulated through a logistic model
using the covariates. Weighted Cox proportional hazards models with a treatment indicator as the
sole covariate were fit as the outcome model to estimate the treatment effect.
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Each simulation scenario was repeated 1,000 times. We estimated bias relative to the true marginal
treatment effect, empirical variance, 95% confidence interval coverage probabilities, power (for
scenarios with non-null treatment effects), and type I error (for scenarios with a null treatment
effect). Power and type I error are estimated for two-sided hypothesis testing using a significance
threshold of 0.05.
We first examined the performance of alternative methods as we varied the ratio of patients in the
intervention arm to standard-of-care patients in the trial. In these analyses neither the proportion
of trial patients in the intervention arm nor the number of EHR patients available as a function of
the number of trial patients affected the pattern of the results. Therefore, only a 2:1 intervention
arm to standard-of-care arm ratio with the same number of EHR patients available as trial patients
are presented here. Sample Kaplan-Meier curves for each treatment hazard ratio and confounding
level combination show the difference in survival over time across the three groups of patients
(Supplemental Figure C.1).
We evaluated the simulation results based on the following criteria: bias, variance, power, coverage,
effective sample size, and type I error rate. Effective sample size was defined as the weighted sum
of subjects included in the analysis.
Simulation code is available on GitHub: https://github.com/joannaharton/DAW
3.3.1. Simulation Results
The results of the simulation study show that fully pooling the data from the available EHR patients
with the trial data results in large biases under all conditions examined (Figure 3.1). As expected,
using only the trial patient data results in negligible bias. The power prior method was also substantially biased across all three α values explored, with α = 0.25 having the least bias and α = 0.75
having the most bias (Figure 3.1). The normalized power prior was biased when the trial size was
100 but displayed minimal bias when the trial size was 1,000. This is explained by the fact that α̂
was estimated to be approximately 0.22-0.36 for the trial size of 100 and 0.01-0.03 for the trial size
of 1,000 (Table 3.4). Therefore, although the normalized power prior approach performed well in
terms of bias this is because little information from the EHR patients was incorporated. Both Lin’s
method and DAW displayed low bias across all scenarios examined. DAW had consistently lower
bias than Lin’s method (Figure 3.1).
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Figure 3.1: Bias for methods when applied to a trial with a 2:1 randomization ratio. PP = power
prior, NPP = normalized power prior, DAW = data-adaptive weighting.
The variances of the estimates reflect the extent to which data from external standard-of-care subjects was incorporated. The trial only approach had the largest variance and full pooling of all EHR
patients with the trial patients had the smallest variance (Figure 3.2). The power prior approach
had variance between the trial only and full pooling methods, with variance inversely proportional
to α. The normalized power prior had substantially smaller variance than the trial only approach
when the trial size was 100 due to the larger α̂s (Figure 3.2, Table 3.4). DAW had smaller variance
than Lin’s method under all conditions examined. This is due to the larger effective sample size for
any given scenario (Figure 3.2, Table 3.3).
DAW was able to achieve the targeted 1:1 intervention to standard-of-care ratio, while Lin’s method
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Figure 3.2: Variance for methods when applied to a trial with a 2:1 randomization ratio. PP = power
prior, NPP = normalized power prior, DAW = data-adaptive weighting.
resulted in substantially smaller effective sample sizes. DAW includes about twice as many external
patients as Lin’s method does in the scenarios examined (Table 3.3).
The full pooling and power prior methods had high power due to their large effective sample sizes
and biased treatment effect estimated which were biased away from the null; however, had the
covariate effects been in the other direction the bias would have been towards the null and these
methods would have had lower power (Figures 3.3, 3.1). The normalized power prior approach
had higher power relative to the trial only method when the trial size was 100 but not when the trial
size is 1,000. Lin’s method and DAW had higher power than the trial only approach and were quite
similar to one another when the trial size was 100; Lin’s method had slightly higher power than
DAW when the trial size was 1,000 (Figure 3.3).
38

Figure 3.3: Power for methods when applied to a trial with a 2:1 randomization ratio. 80% power is
marked with a dotted line. PP = power prior, NPP = normalized power prior, DAW = data-adaptive
weighting.
Clearly, unless the strength of confounding and the trial size are small, full pooling of all EHR
patients or using the power prior with one of the α values examined provides very poor coverage
of the true HR (Figure 3.4). NPP only provides nominal coverage when the trial size is 1,000. Both
Lin’s method and DAW had nominal coverage in all scenarios except under strong confounding
when the trial size was 1,000; in that case Lin’s method had approximately 93-94% coverage and
DAW had 94% coverage except when the marginal treatment ratio is nearly 1, in which case the
coverage dropped to 9% (Figures 3.4, 3.5).
Type I error was controlled at the 5% level when only the trial data were analyzed, and was poorly
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Figure 3.4: Coverage of the true treatment effect hazard ratio when a 95% confidence interval is
used for methods when applied to a trial with a 2:1 randomization ratio. 95% coverage is marked
with a dotted line. PP = power prior, NPP = normalized power prior, DAW = data-adaptive weighting.
controlled under the full pooling and power prior methods (Table 3.2). As expected, NPP controlled
type I error when α̂ was small (i.e., sample size of 1,000) and when there was mild confounding
(Tables 3.2, 3.4). Both Lin’s method and DAW controlled type I error under all scenarios examined
except when there was strong confounding and a trial size of 1,000; type I error was slightly inflated
in this case to around 6% (Table 3.2).

3.4. Metastatic Castration-Resistant Prostate Cancer
The objective of this analysis was to compare the performance of alternative methods described
above in a real-world context in which data were available from a clinical trial and a pseudo EHR
dataset, which was constructed from the standard-of-care arm from the clinical trial. We compared
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Figure 3.5: Zoomed-in view of coverage of the true treatment effect hazard ratio when a 95%
confidence interval is used for methods when applied to a trial with a 2:1 randomization ratio. 95%
coverage is marked with a dotted line. PP = power prior, NPP = normalized power prior, DAW =
data-adaptive weighting.
the effect of abiraterone acetate (an androgen synthesis inhibitor) plus prednisone compared to
prednisone alone on overall survival in patients with metastatic castration-resistant prostate cancer
progressing after chemotherapy. Metastatic castration-resistant prostate cancer (MCRPC) is a type
of advanced prostate cancer that no longer completely responds to treatments that lower testosterone (Tucci, Scagliotti, and Vignani, 2015). The study sample included patients with MCRPC
from a phase 3 randomized double-blind clinical trial (NCT00638690) conducted by Janssen Research & Development, L.L.C.. Complete details of trial eligibility and treatment protocols have
been previously published (Bono et al., 2011).
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Table 3.2: Type I error for trials with a 2:1 randomization ratio. PP = power prior, NPP = normalized
power prior, DAW = data-adaptive weighting.

Trial Only
Full Pooling
PP, α = 0.25
PP, α = 0.5
PP, α = 0.75
NPP
Lin
DAW

Mild Confounding
Trial = 100 Trial = 1,000
0.05
0.051
0.126
0.716
0.053
0.177
0.069
0.403
0.097
0.583
0.061
0.061
0.049
0.046
0.052
0.048

Strong Confounding
Trial = 100 Trial = 1,000
0.052
0.046
0.356
0.999
0.098
0.619
0.192
0.953
0.287
0.996
0.117
0.047
0.044
0.060
0.050
0.059

Table 3.3: Effective sample size for trials with a 2:1 randomization ratio. PP = power prior, NPP =
normalized power prior, DAW = data-adaptive weighting

Trial Only
Full Pooling
PP, α = 0.25
PP, α = 0.5
PP, α = 0.75
NPP
Lin
DAW

Mild Confounding
Trial = 100 Trial = 1,000
100
1000
200
2000
125
1250
150
1500
175
1750
135
1033
116
1166
134
1340

Strong Confounding
Trial = 100 Trial = 1,000
100
1000
200
2000
125
1250
150
1500
175
1750
123
1013
116
1166
134
1340

The clinical trial population included 1,185 patients with MCRPC progressing after taxane chemotherapy (The YODA Project). Patients were randomized in a 2:1 ratio to treatment with abiraterone
acetate plus prednisone or treatment with prednisone alone. Patients were enrolled from 2008 to
2009 and followed for five years, or until death. Treatment arm was classified based on the arm to
which a patient was randomized, regardless of whether they crossed over to open-label abiraterone
acetate at any point (Table 3.5).
The pseudo EHR dataset was constructed by sampling patients from the standard-of-care arm in
the clinical trial such that the baseline covariate distribution of the resultant sample differed between
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Table 3.4: Mean α (alpha) values for normalized power prior approach for trials with a 2:1 randomization ratio. PP = power prior, NPP = normalized power prior, DAW = data-adaptive weighting

HR: 0.5
HR: 0.75
HR: 0.875
HR: 1

Mild Confounding
Trial = 100 Trial = 1,000
0.36
0.03
0.36
0.03
0.36
0.03
0.35
0.03

Strong Confounding
Trial = 100 Trial = 1,000
0.22
0.01
0.23
0.01
0.24
0.01
0.23
0.01

Note: Hazard ratios listed are the conditional treatment hazard ratios as opposed to the marginal treatment hazard ratios.

Table 3.5: Characteristics of patients in the Janssen MCRPC cohort by data source

Age, median (IQR)
ECOG PS, N (%)
0
1
2
Gleason Score, N (%)
1
2
3
4
5
6
7
8
9
10
PSA, median (IQR)
LDH, median (IQR)
ALP, median (IQR)
Hb, median (IQR)
Testosterone, median (IQR)

Pseudo
EHR
N = 1000
69 (63 - 76)

Clinical Trial
Standard-of-Care
Intervention
Arm
Arm
N = 394
N = 791
69 (63 - 75)
69 (64 - 75)

244 (24.4)
572 (57.2)
184 (18.4)

140 (35.5)
209 (53.0)
45 (11.4)

262 (33.1)
447 (56.5)
82 (10.4)

66 (6.6)
11 (1.1)
12 (1.2)
4 (0.4)
19 (1.9)
78 (7.8)
304 (30.4)
152 (15.2)
354 (35.4)
0 (0.0)
399 (98 - 914)
293 (225 - 397)
246 (109 - 447)
11.1 (10.1 - 12.5)
11.5 (5.6 - 20.0)

0 (0.0)
15 (3.8)
1 (0.3)
1 (0.3)
3 (0.8)
2 (0.5)
32 (8.1)
151 (38.3)
76 (19.3)
113 (28.7)
139 (41 - 412)
235 (188 - 321)
126 (83 - 268)
12.0 (10.8 - 12.8)
12.0 (5.7 - 20.0)

1 (0.1)
31 (3.9)
2 (0.3)
3 (0.4)
4 (0.5)
24 (3.0)
76 (9.6)
286 (36.2)
159 (20.1)
205 (25.9)
120 (37 - 354)
222 (187 - 308)
125 (79 - 254)
11.9 (0.9 - 12.9)
13.0 (5.8 - 20.2)

the EHR and clinical trial (Table 3.5, Supplemental Figure C.2). We assume that all patients had
the same set of covariates associated with poor performance for patients with MCRPC recorded
at the baseline encounter (Egevad et al., 2002; Kan et al., 2017; Mori et al., 2019; Nakasian, A.
Rassen, and Franklin, 2017; Sharma, Pal, and Prasad, 2014; Sørensen et al., 1993). Specifically,
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all standard-of-care arm patients were sampled with replacement to create a population of size
10,000 from which we could draw our pseudo EHR sample. Next, each patient was assigned a
probability of sampling according to a non-linear function of the baseline covariates. By constructing
this sampling probability using a non-linear functional form, the estimated on-trial score in the DAW
approach will be mis-specified. This reflects the real-world scenario where we are unlikely to be
able to correctly specify this model. A psuedo EHR sample of size 1,000 was then drawn. The
sampling probabilities were generated such that patients were more likely to be included in the
psuedo EHR if they: were younger, had a higher ECOG score, had a higher Gleason score, had a
higher lab value for PSA, LDH, Hb, and ALP, or had a lower testosterone value. The logistic sigmoid
function was used to relate the ECOG and Gleason scores to the sampling probability in order to
separate out those with high versus low scores rather than having a linear additive effect as the
score increased. The square root of the testosterone lab value was used to shrink the effect of a
high testosterone value on being included in the sample.
Due to missingness in some variables, multiple imputation via predictive mean matching was used
with 5 imputations. The median of the imputed covariates was calculated across imputations and
included in the on-trial score, which is valid in the case where the covariates do not inform treatment
assignment such as in a clinical trial (Mitra and Reiter, 2016). Post-imputation covariate distributions stratified by data source were similar to pre-imputation covariate distributions.
3.4.1. Case Study Results
In order to appropriately interpret the results of the case study we first must evaluate each of
Pocock’s six criteria for the external standard-of-care data (Pocock, 1976). In this case meeting
most of the criteria was trivial due to the fact that the pseudo EHR was created from the standardof-care arm of the clinical trial, except for #6, since the pseudo EHR had patients selected in a
biased fashion such that their covariate distribution was slightly different and their outcomes were
somewhat worse than the clinical trial.
The case study of MCRPC patients had a high rate of death. Of the 791 intervention arm patients
in the trial there were 645 deaths, of the 394 patients receiving the standard-of-care in the trial
there were 331 deaths, and of the 1000 patients in the pseudo EHR there were 937 deaths. The
median survival time was 15.6 months (95% CI: 14.7-16.8) for the intervention arm in the trial ,
11.2 months (95% CI: 10.4-13.3) for the standard-of-care arm of the trial, and 8.0 months (95% CI:
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7.9-8.6) for the pseudo EHR. It is clear that the patients in the pseudo EHR had inferior survival
relative to both arms of the clinical trial. This is likely to be true in reality as patients often receive
more supportive care in a clinical trial than in regular clinical practice and tend to have different
covariate distributions due to restrictive inclusion/exclusion criteria.
The hazard ratio for death for patients on abiraterone acetate plus prednisone as compared to
patients on prednisone alone was 0.86 (95% CI: 0.75-0.98) using only patients enrolled in the
clinical trial. When all pseudo EHR patients were added to the analysis population, the hazard ratio
for death was 0.60 (95% CI: 0.55-0.66) (Figure 3.7). The hazard ratio for death as estimated by
the power prior method with the three different α values were between the trial-only and full pooling
methods, as expected. The normalized power prior method estimated α = 0.004 and therefore
was virtually identical to the trial only method as it effectively borrowed information from only four
registry patients. Lin’s method returned results somewhat similar to the trial only method, with an
estimated hazard ratio of 0.76 (95% CI: 0.68-0.86), adding just over 200 patients to the analysis
(Figure 3.7). The estimated hazard ratio using DAW was 0.85 (95% CI: 0.76-0.94), which is almost
identical to that obtained with the trial only data and also had a smaller confidence interval due to
the fact that 397 patients were added so that the augmented trial had a 1:1 randomization ratio
(Figure 3.7). With the exception of NPP, which only added 4 patients, DAW returned results most
similar to the trial-only result while achieving improved efficiency (Figure 3.7).

Figure 3.6: Kaplan-Meier curves for overall survival patients in the clinical trial and the pseudo EHR.
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Figure 3.7: Hazard ratio for death and 95% confidence intervals (CI) for patients on abiraterone
acetate plus prednisone compared to patients on prednisone alone. FP = full pooling, PP = power
prior, NPP = normalized power prior (α̂ = 0.004), DAW = data-adaptive weighting. Vertical line denotes hazard ratio estimated with only the trial data and the grey band denotes the 95% confidence
interval when only the trial data is used. ESS = estimated sample size.

3.5. Discussion
Data-adaptive weighting allows for the external patients who are most similar to the clinical trial
to be selected and weighted such that the augmented trial has a 1:1 randomization ratio, which
results in minimal bias and tighter confidence intervals as compared to using only the trial data. We
compared the performance of alternative methods for constructing and analyzing a hybrid control
arm in terms of bias, variance, power, confidence interval coverage, and type I error across various
scenarios for trial size, trial randomization ratio, strength of covariate effects, and treatment effect.
Based on the results from our simulation study it is clear that fully pooling external patients with trial
patients has the potential to produce highly biased results, have poor coverage, and substantially
inflate type I error rates. Similarly, the power prior at all three alpha values examined exhibited poor
performance, although results were attenuated towards the trial only analyses. The normalized
power prior either exhibited moderate bias and poor coverage and type I error rate or had little
bias but failed to incorporate much information from the EHR database. The case study examined
here shows how the methods perform on real data when Pocock’s criteria are met when creating a
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hybrid control trial. While observed covariates can be accounted for using on-trial scores as in Lin’s
method and DAW, the other criteria are extremely important to avoid confounding by unobserved
characteristics of patients or their care environment, and creation of a hybrid control arm is not
recommended if they are not met.
Lin’s method has reduced bias and variance compared to the more traditional methods, though
DAW was able to achieve lower bias and variance than Lin’s method. Both methods performed very
similarly with regards to confidence interval coverage and type I error rates. While this may initially
cause one to conclude that Lin’s method and DAW are both good methods to use for hybrid control
arms, there are several points to be made regarding Lin’s method. First, Lin’s method becomes
more difficult to implement with larger trial and/or external data source sizes as optimal matching
can be cumbersome or even impossible with large samples. Second, while the number of EHR
patients selected by Lin’s method nominally produces a 1:1 ratio, weighting by the on-trial score
results in an effective sample size that has fewer standard-of-care than intervention arm patients,
reducing efficiency of this approach. Finally, it is unclear what estimand Lin’s method estimates as
the external patients are weighted by their on-trial score and the trial patients are given a weight
of 1. These issues are addressed by the DAW as the IOW are scaled to ensure that the 1:1 ratio
is preserved and the use of IOW allows one to estimate the estimand of interest: the average
treatment effect for those on-trial.
While our simulation study evaluated a large combination of possible characteristics of a trial and
real-world data source, there are additional factors that could have an effect on the results that
were not examined, including differential covariate effects on the outcome between EHR and trial
patients and potential differential error in outcome ascertainment between EHR and trial patients.
Furthermore, due to the computational demands of Bayesian estimation for these methods, we
have evaluated performance of a frequentist analogue, which targets a different estimand and may
produce different results from a Bayesian implementation, particularly for small sample sizes where
the Bayesian central limit theorem has little effect. One must also consider the direction of the bias
induced by covariates that differ between the trial and real-world populations in order to determine
the effect of the differential covariate distributions on power and type I error. Further, as any propensity score-based method, DAW cannot account for unobserved confounders and performance
is expected to be strongly dependent on the magnitude of unmeasured confounding. Concerns
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regarding misspecification of the propensity score may be mitigated through the use of machinelearning algorithms, such as SuperLearner, which uses cross-validation to compare many types of
prediction models and creates a weighted prediction (Laan, Polley, and Hubbard, 2007).
Based on the results of these simulations and the real-world data example, when working with
hybrid-control arm data we recommend using the DAW method in order to minimize bias and variance while maximizing coverage and properly controlling the type I error rate. Additionally, DAW
estimates the average treatment effect for those on-trial, which is the estimand of interest.

Data Availability
The data that support the findings of this study are available from JANSSEN RESEARCH & DEVELOPMENT, L.L.C. via the Yale University Open Data Access Project. Restrictions apply to
the availability of these data, which were used under license for this study. Data are available
at https://yoda.yale.edu/ with the permission of the Yale University Open Data Access Project.
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CHAPTER 4
I NFORMATIVE P RESENCE B IAS

IN

A NALYSES

OF

E LECTRONIC H EALTH R ECORDS - DERIVED DATA :
A C AUTIONARY N OTE
4.1. Introduction
Electronic health record (EHR) data is an important resource for answering a variety of clinical
and epidemiologic research questions without the need for primary data collection. However, the
pattern of interaction between an individual and the healthcare system, and therefore the amount
and type of information available for each individual, is heterogeneous and driven by the individual’s
specific healthcare needs. Individuals with a greater burden of co-morbidity tend to interact more
frequently with the healthcare system (Goldstein et al., 2016; Phelan, Bhavsar, and Goldstein,
2017; Weiskopf, Rusanov, and Weng, 2013). This can lead to informative presence bias, bias
in the results of analyses based on EHR data due to systematic differences between data that is
observed and data that is not observed due to the structure of the observation process rather than
due to missingness (Goldstein et al., 2019; McCulloch, Neuhaus, and Olin, 2016). This informative
presence bias is particularly problematic in analyses incorporating longitudinal information because
patients with more co-morbid conditions may have more data available in the EHR than their healthy
counterparts (Haneuse and Daniels, 2016).
Informative presence bias can be conceptualized as arising in two ways, Berkson’s bias and differential exposure misclassification. Berkson’s bias is a form of selection bias that arises due to
systematic differences between the study sample and the target population (McGee et al., 2021).
In the setting of longitudinal EHR-derived data, observations consist of a mixture of routine, scheduled visits which are independent of underlying health status, and urgent visits sought in response
to symptoms. Routine visits are considered non-informative and provide unbiased information on
the underlying health status of the population. A patient may also have some visits that are dependent on their underlying health status, referred to as patient-initiated or informative visits. These
informative visits are likely to be associated with underlying health status and therefore can induce
bias in the estimated effect of health status on a health outcome of interest (Phelan, Bhavsar, and
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Goldstein, 2017). Differential exposure misclassification also arises in settings featuring informative
presence if patients who have poorer health have more interaction with the healthcare system. In
this case, EHR data will describe the health status of sicker patients more accurately, while patients
with better overall health who interact with the healthcare system more infrequently will have a less
complete and less accurate characterization of their health status captured in EHR (McGee et al.,
2021).
The challenge of informative observation has been in a variety of scenarios under different conditions. One approach is to analyze longitudinal data containing information on planned visits and
unplanned visits using a linear mixed model with both fixed and random effects for type of visit,
biomarker value, time, and any other covariates of interest as well as the interaction between time
and type of visit (McCulloch, Neuhaus, and Olin, 2016; Neuhaus, McCulloch, and Boylan, 2018).
Chen, et al. examined the scenario where observation times are not independent of the outcome
and proposed a new method to estimate marginal covariate effects by creating a relationship between the (unobserved) marginal density and the observed conditional density by conditioning on
a rank statistic (Chen, Ning, and Cai, 2015). Others have examined such data in a survival context,
such as fitting an additive hazard model rather than a proportional hazards model or jointly modeling survival and longitudinal data when the observation times are reliant on the underlying survival
time (Dai and Pan, 2018; Zhang, Sun, and Sun, 2005).
Goldstein, et al. explored the problem of informative presence bias when using longitudinal biomarker data from EHR to assess the association between a biomarker and a health outcome in a
survival context (Goldstein et al., 2019). This study used simulations to investigate bias in analyses
that use only biomarker values from non-informative visits (i.e. scheduled visits), only biomarker
values from informative visits (i.e. patient-initiated visits), or all observed biomarker values, regardless of the type of visit. They found bias in hazard ratio estimates based on biomarker values
observed only at informative visits but not those based on non-informative visits or combined information from all visit types (Goldstein et al., 2019). Based on these results, they concluded that bias
in hazard ratio estimates is minimal when biomarker values from both types of visits are used as
long as at least 30% of the sample has non-informative visits and concluded that the combination
of informative and non-informative visits in an analysis mitigates potential bias in the effect estimate
(Goldstein et al., 2019). However, in their simulation-based study, Goldstein et al. did not consider
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several realistic scenarios that may typically arise in analyses of EHR data.
In this paper we seek to extend current work, in particular, the findings of the study by Goldstein
et al. to a broader set of EHR-motivated contexts . We explore additional scenarios in which we
consider various settings for informative observation including those with greater variability in the
biomarker over time, variation in the frequency of non-informative visits across individuals, and
varying directions for the effect of the biomarker on both the observation process and the event
process.

4.2. Methods
4.2.1. Notation
Let Bit denote the value of a biomarker for patient i on day t, where t takes values from 1 to mi .
We assume that Bit is only observed when the patient makes a visit to the healthcare system. Let
ViS be an indicator with VitS = 1 indicating that a scheduled visit (non-informative visit) occurs at
time t for patient i and therefore Bit is observed, and 0 otherwise. Let ViP be an indicator with
VitP = 1 indicating that a patient-initiated visit (informative visit) occurs at time t for patient i and
therefore Bit is observed, and 0 otherwise. Let Vi be an indicator that any visit has occurred such
that Vit = max(VitS , VitP ). Additionally, each patient has a set of covariates, Xi . Finally, let Ei be an
indicator such that Eit takes a value of 1 if the event occurs at time t, and 0 otherwise.
4.2.2. Informative visit and health event models
Our investigation is motivated by the setting of real-world EHR data in which patients are assumed
to have a true underlying biomarker trajectory that evolves in continuous time. However, the biomarker value is only captured in the EHR, and therefore known to the researcher, at the time of a
visit to the healthcare system. Each subject has the opportunity to have their biomarker measured
at any given time point; this observation process is a combination of two separate processes, an
informative visit process and a non-informative visit process. The non-informative visit process may
vary across sub-populations of subjects but does not depend on the value of the biomarker. For example, in our case study presented in Section 4.4 focusing on child mortality, non-informative visits
may consist of well-child visits scheduled at standard times throughout childhood. The timing of
these non-informative visits, including well-visits and scheduled follow-ups, may be dependent on
other patient characteristics such as family health history. Explicitly, P (VitS = 1) = f (Xi ), where Xi
is a vector of covariates for patient i and f () is some function. The informative visit process, which
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can be thought of as sick visits or any visit initiated by the patient in response to a health concern,
may be dependent on patient characteristics as well as the underlying value of the biomarker. In
the child mortality case study, our biomarker is body mass index (BMI). In this setting, informative
visits might be prompted by parents’ observation that the child has lost weight or is growing slowly.
Formally, we assume P (VitP = 1) = g(X, Bit ), where g() is some function.
The biomarker is assumed to be connected to a health event of interest, such as death. The probability of a subject experiencing the event of interest at any given time is assumed to be dependent
on patient covariates in addition to the time-varying biomarker value. P (Eit = 1) = h(X, Bit ) where
h() is some function.
4.2.3. Analyzing the association between biomarker and health event
While longitudinal EHR data are often structured as observations in discrete time, such data are
commonly analyzed using methods for time-to-event data in continuous time such as the Cox proportional hazards model with time-varying covariates (Altman and De Stavola, 1994; Lipsitz et al.,
2002; Tsiatis, Degruttola, and Wulfsohn, 1995). In this study, we investigate the following Cox
proportional hazards model,
h(u) = h0 (u) exp{βC Bi (u)},
where Bi (u) is the continuous-time counterpart of the discretely observed Bit . We define Bi (u) =
Bik , tik ≤ u < ti(k+1) . Therefore Bi (u) is a continuous step-wise representation of Bit that carries
the last observed value forward until a new observation is made.
Bi (u) can be defined in multiple ways depending on which biomarker values are included in analysis: including all biomarker values, including only biomarker values observed at non-informative
visits, including only biomarker values observed at informative visits, and including biomarker values observed at both informative and non-informative visits. We note that the first approach, while
ideal, is not feasible with EHR data because biomarker values at most timepoints are unobserved.
Defining Bi (u) using biomarker values captured at different visit types can lead to very different
depictions of the biomarker trajectory. Because Bi (u) takes the last observed value until a new visit
occurs, biomarker values collected at non-informative visits approximates the underlying trajectory
in broad strokes, but the level of detail is lacking, especially if non-informative visits are infrequent
(Figure 4.1). The information obtained from informative visits is distorted, with much more intensive
data collection occurring during periods of high (or low) biomarker values. While this provides high
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quality data during some periods, there is little information collected during other periods. If the biomarker is positively associated with both the informative visit process and health event, a ‘healthy’
patient will have very little data collected while a patient with a highly variable biomarker trajectory
will have much more data collected when the biomarker is high than when it is low. Combining both
types of visits provides a more complete picture when the biomarker value is high (or low) but still
provides some information throughout the follow-up period (Figure 4.1).
A proposed approach to reduce bias in the estimated hazard ratio using this imperfect representation of the biomarker trajectory is to adjust for the intensity of the visit process using the number of
visits accrued within a fixed prior time period. In simulation studies described below, we examine
this approach using a look-back period of 100 days, which Goldstein, et al. found to attenuate most
of the bias in their simulations (Goldstein et al., 2019).

4.3. Simulation Study
4.3.1. Design
We used simulation studies to investigate bias in estimates of the hazard ratio describing the association between the biomarker and health event under a variety of scenarios for the observation
process and volatility of the biomarker trajectory. Data were generated such that each subject
had a biomarker value for every time point t, 0 ≤ t ≤ 730 to represent two years of follow-up. At
day 1, each subject’s biomarker was assumed to take a value of 0. Subsequently, we assumed
Bit = Bi(t−1) + ,  ∼ N (0, σ) for t = 2, . . . , 730. Although few real-world processes feature a
common starting value for the biomarker for all individuals, we use this approach for comparability of our results with those of Goldstein et al. (Goldstein et al., 2019). We investigated several
scenarios with normally distributed starting biomarker values (results not shown). As no difference in the pattern of results was observed across these scenarios, we present only results for
the scenario with all biomarker trajectories starting at 0. No censoring was introduced; patients
were followed for the entire 730-day period or until they had the event. Additionally, an independent covariate, H, which can be thought of as an indicator for family history of the event,
was simulated such that 30% of the sample had H = 1. The time between non-informative visits was simulated from a Poisson(λH ). The informative visit process followed a logistic model,

x
logit(P (VitP = 1)) = −2+βV Bit +log(2)Hi , where logit(x) = log 1−x
. It was possible for any given
day to have both an informative visit and a non-informative visit. The event process also followed a
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Figure 4.1: Trajectories of observed biomarker values for five patients if: all values are observed,
only those at non-informative visits, only those at informative visits, and those at all visits (both
informative and non-informative).
logistic model, logit(P (Eit = 1)) = −8 + βB Bit + log(4)Hi , βB = {log(1.1), log(1.25), log(1.5)}. This
resulted in between 35% and 71% of the sample experiencing the event, with 63%-77% of subjects
with H = 1 experiencing the event and 23%-68% of subjects with H = 0 experiencing the event
(Table 4.1). Relationships between variables are illustrated in Figure 4.2a.
The base scenario off of which all scenarios are varied has σ = 1, λ0 = λ1 = 90, a positive
association between B and VP , and a positive association between B and E. In each simulation
scenario, only one feature of the simulation scenario was varied from its base scenario value. We
investigated values for the variability in the biomarker over time, σ, of 0.2 and 1. All subjects with a
family history of the disease of interest, represented by H = 1 had λ1 = 90, while for subjects with
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Figure 4.2: DAG representing relationships; blue is exposure and orange is outcome of interest.
H = 0 we varied λ0 across values of 90, 182 and 365. The direction of the association between
the biomarker value and the informative visit process was varied to be positive or negative as was
the association between the biomarker and the event process.
Results presented are based on a total sample size of 1,000 patients over 1,000 replicates. The
bias in the marginal effect of the biomarker value on the event of interest, β̂C , was estimated by
taking the average over the 1,000 replicates of the difference between the estimate based on the
Cox models defined above and the estimated β̂C for a super-population of 100,000 subjects with
biomarker values observed at every time point.
4.3.2. Results
Variability of Biomarker
Across scenarios with varying values for σ, between 35% and 71% of the sample experienced the
event, with average follow-up ranging between 348 days and 590 days (Table 4.1). Overall, subjects
with H = 1 had higher rates of the event and therefore shorter follow-up times than subjects with
H = 0. Over 98% of subjects had at least one informative visit, averaging between 43 and 157
informative visits over the two-year follow-up period (Table 4.1). Non-informative visits occurred
roughly every 90 days. Subjects who did not experience the event accrued an average of 7 or 8 noninformative visits over the two-year follow-up period, with the average number of non-informative
visits across the full sample being between 4 and 7 visits (Table 4.1).
Across all three effect sizes, βB = {log(1.1), log(1.25), log(1.5)}, bias was observed in estimates
based on scheduled visits alone, informative visits alone, and all visits (Figure 4.3). This bias
was more pronounced when σ = 1. Additionally, differences across approaches were larger for
larger effect sizes (Figure 4.3). As expected, estimation of the hazard ratio using all values of the
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biomarker resulted in an unbiased estimate. Using only data from non-informative visits resulted
in a hazard ratio estimate that was biased towards the null, while using only data from informative
visits resulted in an upwardly biased hazard ratio estimate (Figure 4.3). The estimate of the hazard
ratio using both informative and non-informative visits had lower bias since these biases are in
opposite directions and cancel one another out.
The scenario with σ = 0.2 and βB = log(1.25) is similar to the main simulation scenario that
Goldstein explored; our scenario differs by including a binary covariate that affects the informative
observation process and the event process as well as by using a slightly different informative event
process (Goldstein et al., 2019). Results for this scenario are similar to those obtained by Goldstein
(Figure 4.3).

Figure 4.3: Marginal effect estimates for varied biomarker variability, σ = {0.2, 1}, and varied conditional effect sizes, βB = {log(1.1), log(1.25), log(1.5)}.
Table 4.1: Sample characteristics for varied biomarker variability, σ = {0.2, 1}, and varied conditional effect sizes, βB = {log(1.1), log(1.25), log(1.5)}. Values presented are for the whole sample
(subset with H=1 / subset with H=0).

βB = log(1.1)
βB = log(1.25)
βB = log(1.5)

σ = 0.2
σ=1
σ = 0.2
σ=1
σ = 0.2
σ=1

Percent
with Event
34.8 (62.9/22.8)
48.1 (67.9/39.6)
38.7 (65.0/27.4)
61.7 (72.6/57.0)
45.4 (66.7/36.3)
71.1 (77.4/68.5)

Avg Length
Follow-up
590 (462/645)
534 (414/585)
576 (448/632)
435 (347/472)
546 (423/599)
348 (285/375)
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Avg Number
Inf. Visits
116 (116/116)
157 (112/176)
105 (101/107)
84 (63/93)
87 (83/89)
43 (36/46)

Avg Number
Non-Inf. Visits
7 (6/8)
6 (5/7)
7 (6/8)
5 (4/6)
7 (5/7)
4 (4/5)

Frequency of Non-Informative Visits
Varying the frequency of non-informative visits for individuals with H = 0, between 48% and 71% of
the sample experienced the event, with average follow-up ranging between 348 days and 534 days
(Table 4.1, σ = 1 rows only). As in results in the prior section, subjects with H = 1 had higher rates
of the event and therefore shorter follow-up times than subjects with H = 0. Over 98% of subjects
had at least one informative visit, averaging between 43 and 157 informative visits over the two-year
follow-up period (Table 4.1). Non-informative visits that occurred roughly every 90 days would allow
subjects who did not experience the event to accrue 7 or 8 non-informative visits over the two-year
follow-up period, those that occurred roughly every 6 months or every year would allow subjects
who did not experience the event to accrue 3-4 or 1-2 non-informative visits, respectively.
The bias seen for estimating the marginal effect using only informative visits does not vary across
these scenarios since the informative visit process is the same in all cases (Figure 4.4). Bias in
the marginal effect using only non-informative visits is similar across the different values for λ0 ,
with bias increasing as the non-informative visits for subjects with H = 0 become more infrequent,
particularly for the larger effect sizes (Figure 4.4). Therefore, the amount of bias for the estimate of
the marginal effect using all visits is also similar across scenarios. Since informative visits greatly
outnumber non-informative visits, the all visits estimate is closer to the informative visits estimate
and moves further toward it as the frequency of scheduled visits decreases (Figure 4.4, Table 4.1).

Figure 4.4: Marginal effect estimates for varied non-informative visit frequency,
λH=0 = {90, 182, 365}, and varied conditional effect sizes,
βB = {log(1.1), log(1.25), log(1.5)}.
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Direction of Association Between Biomarker and Visit Process
In results presented in previous sections, the associations between both the biomarker value and
the event of interest as well as the biomarker value and the informative observation process were
positive. To disambiguate bias towards the null and negative bias, we conducted additional simulations in which the biomarker and informative observation process were negatively associated. The
percent of subjects experiencing the event was between 48% and 71% and the average length of
follow-up was between 348 days and 534 days, with between 4 and 6 non-informative visits accrued
(Table 4.2). The average number of informative visits was affected by the relationship between the
biomarker value and the informative visit process. Therefore, when this relationship was positive
the average number of informative visits was between 43 and 157, while when this relationship was
negative the average number of informative visits was between 209 and 244 (Table 4.2).
When the sign of the observation effect, βV , was positive we found that using only informative
visits was biased away from the null while using only non-informative visits was biased towards the
null; using all visits reduced the bias (Figure 4.5). However, when the sign of βV was negative,
the estimate of βB using only informative visits was also biased towards the null and, therefore,
the combination of both informative and non-informative visits was still biased towards the null
(Figure 4.5). Results for a negative relationship between biomarker value and the event of interest
are shown in Figure D.1 and were performed to confirm there was bias towards or away from the
null as opposed to under- or over-estimation, respectively.
Table 4.2: Sample characteristics when biomarker value has a positive or negative effect on being
observed at an informative visit, and varied conditional effect sizes,
βB = {log(1.1), log(1.25), log(1.5)}. Values presented are for the whole sample (subset with H=1 /
subset with H=0).

βB = log(1.1)
βB = log(1.25)
βB = log(1.5)

βV = log(1.5)
βV = −log(1.5)
βV = log(1.5)
βV = −log(1.5)
βV = log(1.5)
βV = −log(1.5)

Percent
with Event

Average Length
Follow-up

48.1 (67.9/39.6)

534 (414/585)

61.7 (72.6/57.0)

435 (347/472)

71.1 (77.4/68.5)

348 (285/375)
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Avg Number
Inf. Visits
157 (112/176)
244 (222/254)
84 (63/93)
234 (215/242)
43 (36/46)
209 (192/217)

Avg Number
Non-Inf. Visits
6 (5/7)
5 (4/6)
4 (4/5)

Figure 4.5: Marginal effect estimates for biomarker value having a positive or negative effect on being observed at an informative visit, and varied conditional effect sizes, βB =
{log(1.1), log(1.25), log(1.5)}.

Adjusting for Visit Intensity
One proposed method for mitigating bias in effect estimates in the presence of informative observation is to adjust for each subject’s visit intensity over a specified look-back period. In practice
it may be impossible to differentiate between informative and non-informative visits, so the results
shown here adjust for the total number of visits observed in the prior 100 days. In the estimate using data from all visits, adjusting for the number of visits within the past 100 days reduced the bias
compared to the unadjusted estimate regardless of the direction of the effect of the biomarker on
the outcome, suggesting that the adjustment is successful in mitigating bias and does not merely
result in attenuation towards the null (Figure 4.6).

4.4. Case Study
A sample derived from electronic health records data from the Children’s Hospital of Philadelphia
(CHOP) healthcare system was used to explore the effects of informative observation processes
in a real-world setting. A random sample of 10% of children with at least two face-to-face encounters at a site in the CHOP network between 2009 and 2016 were included in this analysis. Data
extracted from the EHR consisted of clinical data collected from CHOP, the CHOP Care Network,
and CHOP Specialty Care and Surgical Centers. Data from all face-to-face encounters for selected
patients between the ages of 12 and 20 were included in this analysis. Our analysis included demographic information (age, sex, race, and ethnicity), biometric measurements (height, weight),
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Figure 4.6: Effect estimates when the visit intensity in the past 100 days is accounted for, and varied
conditional effect sizes, βB = {log(1.1), log(1.25), log(1.5)}.
Table 4.3: Characteristics of patients in the Children’s Hospital of Philadelphia (CHOP) data.

N
Gender
N (%)

Male
Female
White
Black
Race
Asian
N (%)
Other
Multiple
Unknown
Hispanic or Latino
Ethnicity
Not Hispanic or Latino
N (%)
Unknown
Age at first encounter (years), median (Q1-Q3)
First observed BMI z-score, median (Q1-Q3)
Number BMI measurements, median (Q1-Q3)
Length follow-up (years), median (Q1-Q3)

Died
101
56 (55.4)
45 (44.6)
50 (49.5)
31 (30.7)
3 (3.0)
0 (0.0)
2 (2.0)
15 (14.9)
14 (13.9)
58 (57.4)
29 (28.7)
7.4 (2.4-11.9)
0.19 (-0.83-1.05)
15 (4-57)
2.14 (0.33-5.02)

Survived
67787
34865 (51.4)
32922 (48.6)
40229 (59.3)
14784 (21.8)
2422 (3.6)
94 (0.2)
742 (1.1)
9516 (14.0)
4257 (6.3)
53374 (78.7)
10156 (15.0)
5.7 (2.4-11.1)
0.27 (-0.47-1.02)
5 (2-11)
2.81 (0.14-6.71)

and date of death. Height and weight were used to calculate an age- and sex-adjusted body mass
index (BMI) z-score, which is centered at 0 with a standard deviation of 1. The BMI z-score was
considered to be the biomarker of interest in this analysis and the outcome of interest was death.
Calculated BMI z-scores falling outside the range of -4 to 4 (expected to encompass approximately
99.99% of values) were considered to represent data entry errors and excluded from analysis.
Each visit was categorized as ‘outpatient’, ‘inpatient’, or ‘emergency department’, though nearly
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Figure 4.7: BMI z-score trajectories for 20 randomly selected patients who died and 20 randomly
selected patients who did not die. BMI z-score was taken to be constant at the last recorded value
until a new measurement was taken.
25% of visits were missing the visit type classification. Outpatient visits were taken to be a proxy for
non-informative visits and inpatient and emergency department visits were taken to be proxies for
informative visits and were analyzed as such. Data were analyzed with Cox proportional hazards
models with age as the timescale with BMI z-score, race, and ethnicity as covariates; sex and age
were not included as the BMI z-score was age- and sex-adjusted.
Of the 91,860 children who had at least two face-to-face encounters, 67,888 had at least one valid
BMI z-score and comprise the study sample for this analysis. Fifty-one percent of the children in
the sample were male, and 59% were white, with 22% Black, 4% Asian, 1% other or multiple races,
and 14% unknown race (Table 4.3). Most of the sample was not Hispanic or Latino (79%) with 15%
of children not having ethnicity recorded. Overall, the patients had a median age of 5.7 years at
first visit with median BMI z-score at their first visit of 0.27, accrued a median of 5 visits with an
IQR of 2-11 visits, and had a median follow-up period of 2.81 years with an IQR of 0.14-6.71 years
of follow-up (Table 4.3). Furthermore, patients who died had a lower median BMI z-score at first
observation and more BMI measurements than patients who did not die (Table 4.3, Figure 4.7). Of
the 67,888 children in the PBD dataset, 101 deaths were observed (Table 4.3).
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Table 4.4: Hazard ratios and 95% confidence intervals (CI) for death for a one-unit increase in BMI
z-score adjusted for race and ethnicity.

All Visits
Adjusted for Number Visits in Past Year
Emergency / Inpatient Visits
Outpatient Visits

N
67888
67888
6401
60216

HR
0.84
0.87
0.94
0.81

95% CI
(0.70, 1.01)
(0.72, 1.04)
(0.75, 1.18)
(0.67, 0.97)

p-value
0.056
0.13
0.58
0.024

4.4.1. Case Study Results
Overall, only 0.15% of the sample was observed to die, with 99.9% and 99.7% of the sample surviving at ages 10 and 18, respectively (Table 4.3). Using data from all visits, the hazard ratio for death
associated with a one unit positive difference in BMI z-score was estimated to be 0.84 with a 95%
confidence interval of (0.70, 1.01), p=0.056 (Table 4.4). When the number of visits accrued within
the past year was added to the Cox model, the hazard ratio for death associated with a one unit
positive difference in BMI z-score was estimated to be 0.87 with a 95% confidence interval of (0.72,
1.04), p=0.13 (Table 4.4). When only the measurements obtained at visits labeled as ‘emergency’
or ‘inpatient’ were used, only 6401 patients had at least two BMI z-score measurements and the
hazard ratio for death associated with a one unit positive difference in BMI z-score was estimated
to be 0.94 with a 95% confidence interval of (0.75,1.18), p=0.58 (Table 4.4). However, when only
the measurements obtained at visits labeled as ‘outpatient’ were used, 60216 patients had at least
two BMI z-score measurements and the hazard ratio for death associated with a one unit positive
difference in BMI z-score was estimated to be 0.81 with a 95% confidence interval of (0.67,0.97),
p=0.02.

4.5. Discussion
Overall, we found that the risk of bias in analyses using a biomarker subject to informative observation is proportional to variability in the biomarker and the magnitude of the effect of the biomarker
on the outcome. When variability in the biomarker is small, analyses using informative or noninformative visits display little bias. However, for more highly variable biomarkers, bias in estimates
based on informative observations is large and cannot be reliably mitigated by incorporating information from scheduled visits. In settings where bias in estimates based on informative and
non-informative visits is in opposite directions, combining the two kinds of visits appears to reduce
bias. Nonetheless, this is not a reliable approach to reducing bias because it relies on an assump-
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tion that the relationship between the biomarker and the event, as well as the relationship between
the biomarker and the informative visit, are both in the same direction. Bias reduction using all
observed visits will not occur when the biomarker has a positive relationship with the event but has
a negative relationship with the visit process (or vice versa). Adjusting for visit intensity can help
reduce some bias but was not able to completely remove bias seen when estimating the effect of
the biomarker value on the event.
In our simulations, bias due to differences in the rates of non-informative visits across patient subgroups was small. The primary source of bias in parameter estimates using only observations from
non-informative visits was due to misclassification of the exposure due to the ‘lag’ seen in biomarker
value.
Our real-world example using data on children’s age- and sex-adjusted BMI z-scores as a predictor
of death revealed a negative association between BMI z-scores and hazard of death. In our analysis
we adjusted for BMI z-scores obtained at all visit types, with and without adjusting for the number
of visits accrued within the past year, for BMI z-scores obtained at emergency department and
inpatient visits, which are likely to be informative visits, and for BMI z-scores obtained at outpatient
visits, which may have been informative or non-informative visits. The point estimate of the hazard
ratio of interest was similar across the four approaches, and was only statistically significant in
the analysis using outpatient visits alone. While the analysis using only emergency department
and inpatient visits had a much smaller sample size and therefore a wider confidence interval, the
hazard ratio was also estimated to be much closer to one than the other three analyses. The
analysis using only outpatient visits has a sample size almost as large as the entire sample and
has a hazard ratio farther from one; both the relatively narrow confidence interval and stronger
estimated association contribute to significance being obtained in this scenario. The estimate for
the hazard ratio using only inpatient and emergency department visits may also be due to effect
modification, perhaps due to the different racial makeup of patients who receive inpatient care as
opposed to those who receive outpatient care at one of the satellite offices. As evidenced by our
simulation studies, each of these results may be biased towards or away from the null.
Measurement error is a notable source of bias in analyses using only scheduled visits if these analyses assume that biomarkers are constant between observations. Extensive work on joint modeling
of longitudinal and survival data has focused on developing alternative methods to analyzing such
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data that are unbiased. These methods include approaches for analyzing longitudinal data using
informative and/or non-informative visits in a time-to-event context (Dai and Pan, 2018; Han et al.,
2014; Liang, Lu, and Ying, 2009; Qu, Sun, and Song, 2018). Both Liang, et al. and Qu, et al. proposed joint models for longitudinal data that has irregularly spaced and possibly informative visits.
However, their models require the relationships between the random effects to be correctly specified in order to mitigate bias (Liang, Lu, and Ying, 2009; Qu, Sun, and Song, 2018). Han, et al.
proposed an estimator that jointly models the longitudinal process, the observation process, and
the dropout process, but noted that the estimator can be inefficient when censoring is high (Han
et al., 2014). Dai and Pan proposed a jointly modeled estimator that is unbiased when observation
times are non-informative except for the final observation time, which is allowed to be informative
(Dai and Pan, 2018). Therefore, if data are analyzed in a longitudinal rather than survival context a
joint model may be appropriate as long as one considers the potential drawbacks of each method
mentioned previously.
While this study examined the difference between including only informative visits, only non-informative visits, or all visits, information regarding visit type may not be available to the researcher.
It is not uncommon for location of the visit (office visit, walk-in clinic, inpatient, emergency room,
etc.) to be recorded; while one can likely classify all emergency room visits as informative visits
one is not able to classify all office visits as non-informative as some may have been scheduled
only hours prior to the visit. In some contexts, it may be possible to use recorded information on
the indication for the examination to distinguish routine visits from visits scheduled in response to
symptoms (Lange et al., 2015). However, in many settings it will not be possible to conduct analyses
using only informative or non-informative visits. Therefore, in practice it is safest to assume that all
patients have some mixture of informative and non-informative visits in their EHR.
We found that bias exists across the range of biomarker effect sizes evaluated, particularly when the
variability in the biomarker was larger. Our results augment those of the earlier study by Goldstein et
al., which found low bias in estimates using all visits, but focused on a scenario in which variability in
the biomarker was small and the effects of the biomarker on the visit process and outcome were in
the same direction (Goldstein et al., 2019). We found that moving outside of this specialized setting
to evaluate a larger range of biomarker variability and direction of biomarker effects revealed that
bias is often substantial and not mitigated by incorporating information from scheduled visits.
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Understanding the epidemiologic and clinical context for the relationship among the variables under
study as well as their relationship to utilization of healthcare resources is key to assessing the risk
of bias due to informative observation. The variability of the biomarker over time must also be
considered. Analyses using a relatively stable biomarker will have minimal bias, while a volatile
biomarker introduces the possibility of substantial bias. Overall, researchers should proceed with
caution, performing analyses using all visits available with the knowledge that dependent on the
context, the estimated effect may diverge from the true effect. Additionally, sensitivity analyses
using only informative visits and only non-informative visits should be performed to understand
potential bias in results.
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CHAPTER 5
D ISCUSSION
While there are many potential problems associated with using EHR for research, there are many
positive aspects of EHR that make it an excellent resource. Allowing researchers to access vast
quantities of data on diverse populations over long periods of time is incredibly appealing and
many methods have been developed and studied to allow researchers to use EHR data in their
analyses. This dissertation focused on three separate issues regarding the use of EHR data: error
in confounders, the combination of EHR with clinical trial data, and informative presence bias.
Chapter 2 explores a modification of current methods to address error-prone confounders by extending the methods for propensity scores constructed from error-prone covariates. We conclude
that the methods of multiple imputation of propensity scores and two-stage calibration were the
best options for continuous outcomes while the regression calibration-based methods were best
for binary outcomes. While the adjustment methods applied to error-prone covariates did perform
well in certain situations, no single method performed uniformly best across all scenarios; this may
be related to the fact that the gold-standard propensity score and error-prone propensity score
rarely had a linear relationship and instead often had an ‘S’-shaped relationship which may have
disadvantaged the regression calibration-based methods.
While the simulation studies conducted were quite extensive, varying sample size, validation subset
size, outcome type, confounding strength, and error structure, there are additional complexities
that remain to be investigated. The validation sample for all simulations was a simple random
sample. However, this is unlikely to be a realistic scenario, and the setting where the validation
sample is sampled conditional on the outcome should be explored. Additionally, in our simulations
we assumed that if a subject was included in the validation sample they had gold-standard data
available for all covariates, while it is possible that they may only have the gold-standard available
for a subset of the covariates included in the propensity score.
Chapter 3 proposes a new method for incorporating EHR data into randomized clinical trial data
via a hybrid control arm. We find that our new method, DAW, performs well when compared to
other existing power prior-based methods. Another recent method, proposed by Lin, et al. also
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performed well in simulations, though DAW was able to achieve slightly lower bias and variance
(Lin, Gamalo-Siebers, and Tiwari, 2019). A move away from the more traditional power prior-style
methods that require the researcher to select the α value towards methods such as DAW and Lin’s
method that use features of the data to up- or down-weight specific individuals in the external data
is warranted.
The simulations performed varied many factors, including trial size, strength of confounding, randomization ratio in the clinical trial, and true conditional treatment hazard ratio. The work could be
expanded in several ways, one of which is by generating the external data as a heterogenous population rather than a homogeneous one with different covariate distributions than the randomized
clinical trial. Additionally, the covariates could have differential effects on the outcome of interest
dependent on the data source rather than only having different covariate distributions.
Chapter 4 explores more thoroughly the scenario of informative presence bias when longitudinal
data in analyzed in a survival context, specifically with Cox proportional hazards models. If the
biomarker has very little variability we found that it does not matter what visits are used to estimate
the effect but a volatile biomarker can result in large biases. Bias appears to be reduced when all
visits are used if the biomarker has a positive relationship with both the visit process and the event
process, this apparent reduction does not occur when the relationships are in opposite directions.
Adjusting for visit intensity over a given lookback period was able to help reduce some bias but was
not able to eliminate it entirely.
Simulations could be extended in several ways, including by introducing an additional covariate
such that ‘M’-bias is formed. Furthermore, the simulations are currently structured such that observing the biomarker does not affect the value of the biomarker but it could be possible that a high
biomarker may prompt a physician to prescribe a medication that would alter the trajectory of the
biomarker.
EHR data can be used for many different aspects of research, whether it is as a sole data source or
in combination with randomized clinical trial data. While there may be many methods that exist so
far that aim to use EHR data in a comparative effectiveness framework, additional methodological
innovation is needed to ensure the validity of results.
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APPENDIX A
D ERIVATIONS
A.1. Variance of Regression Calibration Estimator
Let us assume that α ⊥ β̃.
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APPENDIX B
S IMULATIONS
B.1. Additional Simulation Results
Table B.1: Model-Based (empirical) standard errors from simulations with continuous outcome, validation size 100, and full sample size 10,000. Standard error calculations restricted to replications
with less than 500% bias.
Confounding

Weak
Confounding

Moderate
Confounding

Strong
Confounding

Error
Structure
A
B
C
D
E
F
A
B
C
D
E
F
A
B
C
D
E
F

EPPS

RC

ERC

MCRC

MIPS

TSC

0.24 (0.14)
0.24 (0.12)
0.24 (0.14)
0.22 (0.13)
0.24 (0.14)
0.25 (0.14)
0.25 (0.14)
0.25 (0.13)
0.25 (0.15)
0.25 (0.14)
0.25 (0.15)
0.26 (0.14)
0.25 (0.14)
0.25 (0.13)
0.25 (0.14)
0.24 (0.14)
0.25 (0.14)
0.25 (0.14)

0.34 (0.3)
0.25 (0.13)
0.39 (0.35)
0.93 (0.99)
36.99 (12.69)
10.05 (7.47)
0.55 (0.55)
0.3 (0.19)
0.57 (0.61)
0.52 (0.53)
1.33 (1.57)
1.03 (1.11)
0.89 (0.9)
0.33 (0.21)
1.05 (1.08)
0.89 (0.86)
0.79 (1.56)
0.6 (1.02)

0.34 (0.31)
0.24 (0.13)
0.38 (0.37)
0.85 (0.98)
2.23 (2.26)
1.99 (2.05)
0.54 (0.53)
0.29 (0.19)
0.55 (0.59)
0.5 (0.52)
1.13 (1.2)
0.94 (0.98)
0.83 (0.84)
0.32 (0.21)
0.96 (0.96)
0.83 (0.8)
0.59 (1.4)
0.58 (1)

0.35 (0.31)
0.25 (0.13)
0.39 (0.37)
0.96 (1.05)
28.67 (13.03)
14.96 (9.32)
0.57 (0.58)
0.3 (0.2)
0.6 (0.65)
0.53 (0.56)
1.73 (2.07)
1.11 (1.22)
0.93 (0.96)
0.33 (0.22)
1.11 (1.17)
0.93 (0.92)
0.97 (1.99)
0.64 (1.07)

0.3 (0.21)
0.59 (0.5)
0.31 (0.22)
0.38 (0.31)
0.55 (0.49)
0.55 (0.48)
0.67 (0.65)
0.35 (0.33)
0.71 (0.69)
0.68 (0.61)
0.8 (0.82)
0.79 (0.75)
0.85 (0.91)
0.39 (0.4)
0.9 (0.96)
0.89 (0.86)
0.94 (1.05)
0.94 (0.97)

0.61 (0.42)
0.29 (0.15)
0.69 (0.49)
1.09 (0.93)
1.33 (1.8)
1.32 (1.93)
0.72 (0.73)
0.29 (0.24)
0.79 (0.81)
0.69 (0.73)
0.92 (1.23)
0.79 (1.23)
0.81 (0.96)
0.28 (0.29)
0.88 (1.04)
0.69 (0.88)
1.01 (1.49)
0.91 (1.46)

Table B.2: Model-Based (empirical) standard error from simulations with binary outcome, validation
size 100, and full sample size 10,000. Standard error calculations restricted to replications with
less than 500% bias.
Confounding

Weak
Confounding

Moderate
Confounding

Strong
Confounding

Error
Structure
A
B
C
D
E
F
A
B
C
D
E
F
A
B
C
D
E
F

EPPS

RC

ERC

MCRC

MIPS

TSC

0.06 (0.05)
0.06 (0.05)
0.06 (0.05)
0.06 (0.05)
0.06 (0.05)
0.07 (0.07)
0.06 (0.05)
0.06 (0.05)
0.06 (0.05)
0.06 (0.05)
0.06 (0.05)
0.06 (0.06)
0.06 (0.05)
0.06 (0.05)
0.06 (0.05)
0.06 (0.05)
0.06 (0.05)
0.06 (0.06)

0.06 (0.05)
0.06 (0.05)
0.06 (0.05)
0.07 (0.07)
0.95 (0.51)
0.65 (0.45)
0.12 (0.11)
0.07 (0.06)
0.12 (0.12)
0.12 (0.11)
0.24 (0.24)
0.21 (0.2)
0.14 (0.14)
0.07 (0.06)
0.15 (0.15)
0.15 (0.14)
0.25 (0.25)
0.21 (0.21)

0.06 (0.05)
0.06 (0.05)
0.06 (0.05)
0.07 (0.07)
0.5 (0.42)
0.44 (0.37)
0.11 (0.11)
0.07 (0.06)
0.12 (0.12)
0.12 (0.1)
0.22 (0.21)
0.2 (0.19)
0.14 (0.13)
0.07 (0.06)
0.15 (0.14)
0.15 (0.13)
0.23 (0.21)
0.2 (0.19)

0.06 (0.05)
0.06 (0.05)
0.06 (0.05)
0.08 (0.08)
2.02 (0.53)
1.08 (0.47)
0.12 (0.12)
0.07 (0.06)
0.13 (0.13)
0.12 (0.11)
0.27 (0.26)
0.22 (0.22)
0.14 (0.14)
0.07 (0.06)
0.16 (0.16)
0.15 (0.15)
0.31 (0.28)
0.23 (0.23)

0.07 (0.06)
0.09 (0.09)
0.07 (0.06)
0.08 (0.07)
0.16 (0.12)
0.14 (0.11)
0.13 (0.14)
0.07 (0.08)
0.14 (0.15)
0.14 (0.14)
0.16 (0.18)
0.16 (0.16)
0.16 (0.18)
0.08 (0.08)
0.18 (0.19)
0.18 (0.17)
0.19 (0.22)
0.19 (0.2)

0.08 (0.1)
0.05 (0.06)
0.09 (0.11)
0.14 (0.15)
0.17 (0.25)
0.19 (0.32)
0.16 (0.19)
0.05 (0.06)
0.17 (0.21)
0.15 (0.19)
0.2 (0.28)
0.18 (0.32)
0.19 (0.23)
0.06 (0.06)
0.2 (0.24)
0.17 (0.23)
0.23 (0.3)
0.21 (0.33)
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B.2. Additional Simulation Study - Interaction between X and Z
The following simulation results use a data generating model that contains an interaction between
X and Z and fits a correctly specified propensity score model.

Figure B.1: Bias for the continuous outcome (true value = 10) with validation size 100 and full
sample size 10,000 over three strengths of confounding and six error structures. Intervals displayed
are from the 2.5 percentile to 97.5 percentile of the replications with less than 500% bias out of
10,000 total replications.
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Figure B.2: Bias for the binary outcome (true value = 0.22) with validation size 100 and full sample
size 10,000 over three different amounts of confounding and six different error structures. Intervals
displayed are from the 2.5 percentile to 97.5 percentile of the replications with less than 500% bias
out of 10,000 total replications.
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Table B.3: 95% confidence interval coverage probabilities of valid simulations with continuous outcome, validation size 100, and full sample size 10,000

Confounding

Weak
Confounding

Moderate
Confounding

Strong
Confounding

Error
Structure
A
B
C
D
E
F
A
B
C
D
E
F
A
B
C
D
E
F

EPPS

RC

ERC

MCRC

MIPS

TSC

0%
97.62%
0%
0%
0%
0%
0%
92.7%
0%
0%
0%
0%
0%
94.68%
0%
0%
0%
0%

91.06%
98.3%
90.38%
90.73%
99.45%
95.58%
79.7%
96.38%
75.56%
79.62%
78.02%
61.02%
79%
96.1%
74.7%
81.09%
70.35%
59.79%

89.8%
97.89%
89.71%
89.65%
94.83%
94.26%
82.55%
96.21%
82.04%
82.46%
90.28%
76.76%
83.94%
95.68%
82.46%
83.8%
88%
75.71%

87.78%
96.7%
86.53%
87.64%
99.02%
90.47%
76.05%
94.59%
72.11%
77.4%
72.26%
59.53%
75.75%
94.56%
71.36%
77.87%
65.62%
58.33%

90.21%
88.56%
90.14%
91.04%
88.1%
88.22%
83.29%
71.3%
81.97%
84.3%
72.98%
82.79%
79%
65.76%
78.46%
80.15%
72.21%
81.36%

87.9%
79.57%
88.06%
80.74%
87.28%
88.12%
68.77%
65.74%
69.68%
58.6%
70.55%
68.03%
64.87%
62.76%
64.2%
53.29%
67.66%
63.21%
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Table B.4: 95% confidence interval coverage probabilities of valid simulations with binary outcome,
validation size 100, and full sample size 10,000

Confounding

Weak
Confounding

Moderate
Confounding

Strong
Confounding

Error
Structure
A
B
C
D
E
F
A
B
C
D
E
F
A
B
C
D
E
F

EPPS

RC

ERC

MCRC

MIPS

TSC

2.63%
96.75%
0.21%
0.75%
0%
0%
0%
50.16%
0%
0.06%
0%
0%
0%
31.4%
0%
0.41%
0%
0%

49.83%
96.54%
29.46%
37.86%
42.98%
0.03%
8.05%
51.49%
0.33%
50.55%
0%
0%
7.46%
33.3%
0.12%
68.25%
0%
0%

50.5%
96.35%
30.34%
38.41%
69.32%
0.19%
8.83%
51.14%
0.38%
52%
0.01%
0%
8.41%
32.66%
0.14%
69.58%
0.04%
0%

51.36%
96.5%
30.73%
39.15%
64.37%
0.96%
9.01%
51.63%
0.42%
51.81%
0.06%
0%
8.6%
33.3%
0.11%
68.99%
0.06%
0%

92%
72.33%
90.84%
93.49%
83.77%
84%
88.19%
67.28%
87.62%
86.26%
84.17%
83.37%
86.93%
66.11%
86.22%
84.29%
82.62%
80.77%

91.85%
94.24%
91.3%
91.4%
82.92%
88.77%
86.65%
32.38%
86.87%
81.38%
87.53%
86.6%
84.75%
19.53%
85.81%
78.59%
86.7%
84.69%

Table B.5: Model-Based (empirical) standard errors from simulations with continuous outcome, validation size 100, and full sample size 10,000. Standard error calculations restricted to replications
with less than 500% bias.
Confounding

Weak
Confounding

Moderate
Confounding

Strong
Confounding

Error
Structure
A
B
C
D
E
F
A
B
C
D
E
F
A
B
C
D
E
F

EPPS

RC

ERC

MCRC

MIPS

TSC

0.17 (0.15)
0.16 (0.14)
0.17 (0.15)
0.16 (0.15)
0.27 (0.16)
0.22 (0.15)
0.21 (0.2)
0.22 (0.21)
0.21 (0.2)
0.21 (0.21)
0.22 (0.21)
0.2 (0.18)
0.22 (0.21)
0.23 (0.22)
0.22 (0.21)
0.22 (0.23)
0.22 (0.22)
0.2 (0.19)

1.01 (1.05)
0.3 (0.26)
1.14 (1.17)
0.98 (1)
9.67 (5.7)
3.53 (3.61)
1.53 (1.5)
0.43 (0.39)
1.75 (1.7)
1.31 (1.49)
3.95 (3.55)
1.99 (1.97)
1.66 (1.58)
0.46 (0.44)
1.91 (1.8)
1.38 (1.57)
3.97 (3.36)
1.97 (1.95)

0.85 (0.93)
0.3 (0.26)
0.92 (1.01)
0.83 (0.91)
1.55 (1.55)
1.43 (1.42)
1.24 (1.27)
0.43 (0.39)
1.35 (1.36)
1.11 (1.26)
1.86 (1.81)
1.45 (1.49)
1.33 (1.34)
0.45 (0.44)
1.45 (1.44)
1.17 (1.32)
1.95 (1.89)
1.48 (1.49)

1.04 (1.1)
0.31 (0.27)
1.17 (1.23)
1.01 (1.05)
27.01 (7.73)
4.1 (4.04)
1.58 (1.59)
0.44 (0.41)
1.82 (1.82)
1.36 (1.55)
4.34 (3.9)
2.07 (2.09)
1.72 (1.69)
0.47 (0.46)
2 (1.92)
1.42 (1.65)
4.34 (3.71)
2.05 (2.08)

0.87 (0.94)
1.11 (1.33)
0.93 (1.01)
0.85 (0.89)
1.2 (1.38)
1.18 (1.37)
1.08 (1.35)
0.9 (1.58)
1.1 (1.41)
1.06 (1.27)
1 (1.59)
1.11 (1.42)
1.11 (1.42)
0.85 (1.63)
1.13 (1.48)
1.11 (1.36)
0.99 (1.58)
1.14 (1.45)

0.75 (0.93)
0.18 (0.27)
0.8 (1)
0.6 (0.89)
1.11 (1.41)
1.1 (1.36)
0.72 (1.4)
0.21 (0.44)
0.77 (1.47)
0.55 (1.35)
0.95 (1.77)
0.79 (1.56)
0.71 (1.51)
0.22 (0.49)
0.76 (1.61)
0.54 (1.45)
0.91 (1.84)
0.73 (1.62)
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Table B.6: Model-Based (empirical) standard error from simulations with binary outcome, validation
size 100, and full sample size 10,000. Standard error calculations restricted to replications with
less than 500% bias.
Confounding

Weak
Confounding

Moderate
Confounding

Strong
Confounding

Error
Structure
A
B
C
D
E
F
A
B
C
D
E
F
A
B
C
D
E
F

EPPS

RC

ERC

MCRC

MIPS

TSC

0.06 (0.05)
0.06 (0.06)
0.06 (0.05)
0.06 (0.05)
0.07 (0.06)
0.06 (0.06)
0.08 (0.07)
0.09 (0.08)
0.08 (0.07)
0.08 (0.07)
0.08 (0.07)
0.08 (0.07)
0.09 (0.08)
0.09 (0.08)
0.09 (0.08)
0.09 (0.07)
0.09 (0.08)
0.08 (0.08)

0.08 (0.07)
0.06 (0.06)
0.08 (0.07)
0.07 (0.07)
2.36 (1.62)
0.16 (0.16)
0.11 (0.1)
0.09 (0.08)
0.11 (0.1)
0.11 (0.1)
0.25 (0.23)
0.11 (0.1)
0.12 (0.11)
0.1 (0.09)
0.12 (0.11)
0.12 (0.11)
0.27 (0.24)
0.12 (0.11)

0.08 (0.07)
0.06 (0.06)
0.08 (0.07)
0.07 (0.07)
0.54 (0.64)
0.15 (0.13)
0.11 (0.1)
0.09 (0.08)
0.11 (0.1)
0.11 (0.1)
0.24 (0.18)
0.11 (0.1)
0.12 (0.11)
0.1 (0.09)
0.12 (0.11)
0.12 (0.11)
0.26 (0.18)
0.12 (0.11)

0.08 (0.07)
0.06 (0.06)
0.08 (0.07)
0.07 (0.07)
5.22 (2.12)
0.19 (0.22)
0.11 (0.1)
0.09 (0.08)
0.11 (0.1)
0.11 (0.1)
0.28 (0.27)
0.11 (0.1)
0.12 (0.11)
0.1 (0.09)
0.12 (0.11)
0.12 (0.11)
0.29 (0.27)
0.12 (0.11)

0.13 (0.13)
0.18 (0.29)
0.13 (0.14)
0.12 (0.12)
0.27 (0.31)
0.21 (0.26)
0.34 (0.37)
0.38 (0.62)
0.36 (0.39)
0.33 (0.32)
0.46 (0.57)
0.4 (0.43)
0.38 (0.41)
0.4 (0.67)
0.4 (0.45)
0.37 (0.36)
0.51 (0.61)
0.43 (0.45)

0.14 (0.2)
0.06 (0.06)
0.16 (0.23)
0.13 (0.19)
0.28 (0.48)
0.27 (0.39)
0.35 (0.53)
0.09 (0.12)
0.37 (0.56)
0.27 (0.39)
0.51 (0.78)
0.39 (0.59)
0.39 (0.61)
0.1 (0.14)
0.42 (0.67)
0.3 (0.44)
0.55 (0.84)
0.4 (0.63)
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APPENDIX C
S UPPLEMENTARY F IGURES

FOR

C HAPTER 3

C.1. Supplementary Figures for Chapter 3

Figure C.1: Kaplan-Meier curves for sample simulated datasets for each of four conditional treatment hazard ratios and two strengths of confounding.
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Figure C.2: Covariate distributions in the clinical trial and pseudo EHR.
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Figure C.3: On-trial score distributions for patients in the clinical trial and the pseudo EHR. Vertical
lines denote mean on-trial score in each group.
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APPENDIX D
S UPPLEMENTARY F IGURES

FOR

C HAPTER 4

D.1. Supplementary Figures for Chapter 4

Figure D.1: Marginal effect estimates for biomarker value having a positive or negative effect on being observed at an informative visit, and varied conditional effect sizes, βB =
{−log(1.1), −log(1.25), −log(1.5)}.

Figure D.2: Biomarker values and number of visits accrued within the past 100 days for five random
subjects.

78

BIBLIOGRAPHY
Abernethy, AP, Gippetti, J, Parulkar, R, and Revol, C (2017). Use of electronic health record data
for quality reporting. Journal of oncology practice 13.8, 530–534.
Altman, DG and De Stavola, BL (1994). Practical problems in fitting a proportional hazards model to
data with udated measurements of the covariates. Statistics in medicine 13.4. ISBN: 0277-6715
Publisher: Wiley Online Library, 301–341.
Berger, ML, Curtis, MD, Smith, G, Harnett, J, and Abernethy, AP (2016). Opportunities and challenges in leveraging electronic health record data in oncology. Future Oncology 12.10, 1261–
1274.
Bono, JS de, Logothetis, CJ, Molina, A, Fizazi, K, North, S, Chu, L, Chi, KN, Jones, RJ, Goodman, OBJ, Saad, F, Staffurth, JN, Mainwaring, P, Harland, S, Flaig, TW, Hutson, TE, Cheng,
T, Patterson, H, Hainsworth, JD, Ryan, CJ, Sternberg, CN, Ellard, SL, Fléchon, A, Saleh, M,
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